Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative

Emerging Infectious Diseases
Volume 19, Number 12—December 2013
http://www.cdc.gov/ncidod/EID/index.htm

Perspective
Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative
Carol Rubin , Tanya Myers, William Stokes, Bernadette Dunham, Stic Harris, Beth Lautner, and Joseph Annelli
http://wwwnc.cdc.gov/eid/article/19/12/12-1659_article.htm

Abstract
Human health is inextricably linked to the health of animals and the viability of ecosystems; this is a concept commonly known as One Health. Over the last 2 decades, the Institute of Medicine (IOM) and the National Research Council (NRC) have published consensus reports and workshop summaries addressing a variety of threats to animal, human, and ecosystem health. We reviewed a selection of these publications and identified recommendations from NRC and IOM/NRC consensus reports and from opinions expressed in workshop summaries that are relevant to implementation of the One Health paradigm shift. We grouped these recommendations and opinions into thematic categories to determine if sufficient attention has been given to various aspects of One Health. We conclude that although One Health themes have been included throughout numerous IOM and NRC publications, identified gaps remain that may warrant targeted studies related to the One Health approach.

A mathematical model to predict the risk of hepatitis B infection through needle/syringe sharing in mass vaccination

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 23 November 2013]

Research Article
A mathematical model to predict the risk of hepatitis B infection through needle/syringe sharing in mass vaccination
Etsuji Okamoto
Infectious Diseases of Poverty 2013, 2:28  doi:10.1186/2049-9957-2-28
Published: 19 November 2013
http://www.idpjournal.com/content/2/1/28/abstract

Abstract (provisional)
Background
The Japanese Government settled a class litigation case with hepatitis B virus (HBV) carriers who claim to have been infected through needle/syringe sharing in mass vaccination with a blanket compensation agreement. However, it is difficult to estimate how many of the present HBV carriers were infected horizontally from mass vaccination and how many were infected vertically from mothers.

Methods
A mathematical model to predict the risk of infection through needle/syringe sharing in mass vaccination was proposed and a formula was developed. The formula was presented in a logarithmic graph enabling users to estimate how many people will be infected if a needle/syringe is shared by how many people for how many times under certain probability of infection. The formula was then applied to the historical data of mass tuberculin skin tests (TSTs) and BCG inoculation, from which a best estimate of how much needle/syringe sharing was practiced in different birth cohorts was determined.

Results
For the oldest cohort born between 1951 and 1955, the prevalence of HBV carriers—0.65% at birth through vertical transmission—more than doubled in 1995 (1.46% ) through horizontal transmission. If the probability of infection through needle/syringe sharing is assumed to be 10% , it is theoretically likely that an average of five or more people shared a needle/syringe four times to achieve the prevalence of HBV carriers in 1995. However, for the youngest cohort born between 1981 and 1985, the effects of needle/syringe sharing were negligible because the later prevalence of HBV carriers was lower than the prevalence at birth.

Conclusions
More than half of the HBV carriers born in the early 1950s might have contracted the disease by mass vaccinations. Japan’s experience needs to be shared with other countries as a caution in conducting mass vaccination programs under scarce needle/syringe supply.

Potential Impact of the US President’s Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries

Journal of Infectious Diseases
Volume 208 Issue 12 December 15, 2013
http://jid.oxfordjournals.org/content/current

Potential Impact of the US President’s Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries
Viviane D. Lima1,2, Reuben Granich3, Peter Phillips1,4, Brian Williams5 and Julio S. G. Montaner1,2
http://jid.oxfordjournals.org/content/208/12/2075.abstract

Abstract
Background. There are limited data measuring the impact of expanded human immunodeficiency virus (HIV) prevention activities on the tuberculosis epidemic at the country level. Here, we characterized the potential impact of the US President’s Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis epidemic in sub-Saharan Africa.

Methods. We selected 12 focus countries (countries receiving the greatest US government investments) and 29 nonfocus countries (controls). We used tuberculosis incidence and mortality rates and relative risks to compare time periods before and after PEPFAR’s inception, and a tuberculosis/HIV indicator to calculate the rate of change in tuberculosis incidence relative to the HIV prevalence.

Results. Comparing the periods before and after PEPFAR’s implementation, both tuberculosis incidence and mortality rates have diminished significantly and to a higher degree in focus countries. The relative risk for developing tuberculosis, comparing those with and without HIV, was 22.5 for control and 20.0 for focus countries. In most focus countries, the tuberculosis epidemic is slowing down despite some regions still experiencing an increase in HIV prevalence.

Conclusions. This ecological study showed that PEPFAR had a more consistent and substantial effect on HIV and tuberculosis in focus countries, highlighting the likely link between high levels of HIV investment and broader effects on related diseases such as tuberculosis.

Lancet Series – Bangladesh: Innovation for Universal Health Coverage

The Lancet  
Nov 23, 2013  Volume 382  Number 9906  p1679 – 1756  e25
http://www.thelancet.com/journals/lancet/issue/current

Series
Bangladesh: Innovation for Universal Health Coverage
The Bangladesh paradox: exceptional health achievement despite economic poverty
A Mushtaque R Chowdhury, Abbas Bhuiya, Mahbub Elahi Chowdhury, Sabrina Rasheed, Zakir Hussain, Lincoln C Chen
Preview |
Bangladesh, the eighth most populous country in the world with about 153 million people, has recently been applauded as an exceptional health performer. In the first paper in this Series, we present evidence to show that Bangladesh has achieved substantial health advances, but the country’s success cannot be captured simplistically because health in Bangladesh has the paradox of steep and sustained reductions in birth rate and mortality alongside continued burdens of morbidity. Exceptional performance might be attributed to a pluralistic health system that has many stakeholders pursuing women-centred, gender-equity-oriented, highly focused health programmes in family planning, immunisation, oral rehydration therapy, maternal and child health, tuberculosis, vitamin A supplementation, and other activities, through the work of widely deployed community health workers reaching all households.

Bangladesh: Innovation for Universal Health Coverage
Harnessing pluralism for better health in Bangladesh
Syed Masud Ahmed, Timothy G Evans, Hilary Standing, Simeen Mahmud
Preview |
How do we explain the paradox that Bangladesh has made remarkable progress in health and human development, yet its achievements have taken place within a health system that is frequently characterised as weak, in terms of inadequate physical and human infrastructure and logistics, and low performing? We argue that the development of a highly pluralistic health system environment, defined by the participation of a multiplicity of different stakeholders and agents and by ad hoc, diffused forms of management has contributed to these outcomes by creating conditions for rapid change.

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases
Dec 2013  Volume 13  Number 12  p995 – 1098
http://www.thelancet.com/journals/laninf/issue/current

A rare success for cholera vaccines
Saranya Sridhar a, Narendra Kumar Arora b
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970296-2/fulltext?_eventId=login

Cholera is a truly neglected infectious disease that is endemic in most parts of Africa and Asia. Despite an estimated annual burden of 2–4 million cases,1 it garners public attention only when outbreaks rampage through disaster-struck populations.2 Control of cholera depends on the long-term strategy of improving water quality and sanitation systems, but an effective vaccine conferring durable protection could offer an additional weapon in the depleted armoury of prevention strategies for this disease.

In 2001, WHO prequalified the licensed oral cholera vaccine Dukoral (SBL Vaccin AB, Sweden) for purchase by UN organisations.3 However, this vaccine is expensive, its efficacy lasts for only 2 years,4 and it is primarily used to protect travellers.3 In a technology transfer that should serve as a model for vaccine development, a modified version of the vaccine (Shanchol, Shantha Biotechnics, India) was manufactured and licensed in India in 2009. Shanchol was prequalified by the WHO in 2011. A field trial5 showed 67% cumulative efficacy in the first 2 years after vaccination. At that time, we sounded a note of cautious optimism and awaited the results of longer follow-up since other promising cholera vaccines with similar efficacy had failed to deliver longlasting protection.6

In The Lancet Infectious Diseases, Sujit Bhattacharya and colleagues7 report on whether Shanchol was protective over 5 years in a follow-up of 66 900 participants in a cluster-randomised placebo-controlled trial in Kolkata, India. The whole-cell vaccine containing killed strains from the O1 and O139 serogroups was given in two doses 2 weeks apart to non-pregnant individuals older than 1 year. The vaccine showed 65% (95% CI lower boundary of 52%) cumulative efficacy in the 5 year period for prevention of cholera episodes severe enough for individuals to seek treatment. This cholera vaccine is the first in the long history of cholera vaccine development to show more than 50% efficacy lasting up to 5 years. However, in children aged 1–5 years, who are at greatest risk of disease, the vaccine conferred only 42% cumulative efficacy (95% CI lower boundary of 5%) and too few cases occurred during the fifth year of follow-up to judge whether protection in these children lasted into the fifth year after vaccination. This lower level of protection is compounded by the difficulty of delivering oral vaccination to young children in poor sanitary and hygiene conditions. Nonetheless, we believe this result of an unprecedented level of long-term efficacy will be a giant leap forward for global control of cholera.

Despite this advance, questions remain. How do we improve vaccine efficacy in young children? The cholera community might learn from influenza vaccination, in which live attenuated vaccines are most efficacious in children and killed vaccines most efficacious in adults. Perhaps more effort needs to be placed on development, improvement, and testing of new and old attenuated cholera vaccines.8 A booster dose 2–3 years after the first vaccination might be necessary. Would the vaccine work equally well in areas that are not cholera endemic?      In endemic cholera areas, such as the Kolkata trial site,7 the vaccine might boost existing naturally acquired immunity. This boosting effect is given more credence by trial results showing an increased efficacy in the fourth and fifth year of the study, especially in adults, after a large cholera outbreak in the third year. Whether the vaccine will be equally efficacious in immunologically naive individuals, especially in the context of cholera outbreaks, is unknown.    Individuals with HIV infection and those who are pregnant and elderly are the other high-risk populations in whom this vaccine needs to be assessed.

Vaccine efficacy was shown only against the O1 strain circulating in the study population. Efficacy against the O139 strains and newly emergent O1 strains expressing the classical toxins should be investigated.3 Resolution of whether the vaccine can reduce infection or transmission and not just protect against severe disease would help to further strengthen the case for vaccination.

We are only allowed the luxury of posing such questions because today’s study offers the cholera community an effective vaccine conferring durable protection. Despite all these unresolved issues, the need for an affordable cholera vaccine for international use has now been partly fulfilled. The focus now shifts to global policy makers and individual governments as they determine how to translate these study results into effective public good. While we celebrate a rare success story, perhaps the first in the WHO supported Decade of Vaccines collaboration, we need to seize this opportunity to transform global cholera control before we are once again overwhelmed by the next, inevitable, outbreak.

   References
1 M Ali, AL Lopez, YA You et al.
The global burden of cholera
Bull World Health Organ, 90 (2012), pp. 209–218A
2 Update: outbreak of cholera—Haiti, 2010
MMWR Morb Mortal Wkly Rep, 59 (2010), pp. 1586–1590
3 WHO Cholera, 2012
Wkly Epidemiol Rec, 88 (2013), pp. 321–334
4 FP Van Loon, JD Clemens, J Chakraborty et al.
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up
Vaccine, 14 (1996), pp. 162–166
5  D Sur, AL Lopez, S Kanungo et al.
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
Lancet, 374 (2009), pp. 1694–1702
6 S Sridhar
An affordable cholera vaccine: an important step forward
Lancet, 374 (2009), pp. 1658–1660
7 SK Bhattacharya, D Sur, M Ali et al.
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial
Lancet Infect Dis (2013) published online Oct 18. http://dx.doi.org.ezproxy.med.nyu.edu/10.1016/S1473-3099(13)70273-1
8  M Pastor, JL Pedraz, A Esquisabel
The state-of-the-art of approved and under-development cholera vaccines
Vaccine, 31 (2013), pp. 4069–4078

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial
Sujit K Bhattacharya MD a b, Dipika Sur MD a, Dr Mohammad Ali PhD c, Suman Kanungo DIH a, Young Ae You MS c, Byomkesh Manna PhD a, Binod Sah MBBS c, Swapan K Niyogi MD a, Jin Kyung Park PhD c, Banwarilal Sarkar PhD a, Mahesh K Puri MSc c, Deok Ryun Kim MS c, Jacqueline L Deen MD d, Jan Holmgren PhD e, Rodney Carbis BSc c, Mandeep Singh Dhingra MD f, Allan Donner PhD g, G Balakrish Nair PhD a, Anna Lena Lopez MD c h, Thomas F Wierzba PhD c, John D Clemens MD c i j
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970273-1/abstract
Summary
Background
Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India.

Methods
In our double-blind, cluster-randomised, placebo-controlled trial, we assessed incidence of cholera in non-pregnant individuals older than 1 year residing in 3,933 dwellings (clusters) in Kolkata, India. We randomly allocated participants, by dwelling, to receive two oral doses of modified killed bivalent whole-cell cholera vaccine or heat-killed Escherichia coli K12 placebo, 14 days apart. Randomisation was done by use of a computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for patients to seek treatment in a health-care facility. We identified culture-confirmed cholera cases among participants seeking treatment for diarrhoea at a study clinic or government hospital between 14 days and 1,825 days after receipt of the second dose. We assessed vaccine protection in a per-protocol population of participants who had completely ingested two doses of assigned study treatment.

Findings
69 of 31,932 recipients of vaccine and 219 of 34,968 recipients of placebo developed cholera during 5 year follow-up (incidence 2.2 per 1000 in the vaccine group and 6.3 per 1000 in the placebo group). Cumulative protective efficacy of the vaccine at 5 years was 65% (95% CI 52-74; p<0·0001), and point estimates by year of follow-up suggested no evidence of decline in protective efficacy.

Interpretation
Sustained protection for 5 years at the level we reported has not been noted previously with other oral cholera vaccines. Established long-term efficacy of this vaccine could assist policy makers formulate rational vaccination strategies to reduce overall cholera burden in endemic settings.

Funding
Bill & Melinda Gates Foundation and the governments of South Korea and Sweden.

Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China

New England Journal of Medicine
November 21, 2013  Vol. 369 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Original Article
Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China
Hui-Ming Luo, M.D., Yong Zhang, M.D., Ph.D., Xin-Qi Wang, M.D., Wen-Zhou Yu, M.D., Ph.D., M.P.H., Ning Wen, M.Sc., Dong-Mei Yan, M.Sc., Hua-Qing Wang, M.D., Ph.D., Fuerhati Wushouer, M.D., Hai-Bo Wang, M.D., Ph.D., Ai-Qiang Xu, M.D., Jing-Shan Zheng, M.D., De-Xin Li, M.D., Hui Cui, B.Sc., Jian-Ping Wang, M.Sc., Shuang-Li Zhu, B.Sc., Zi-Jian Feng, M.D., Fu-Qiang Cui, M.D., Ph.D., M.P.H., Jing Ning, B.Sc., Li-Xin Hao, M.D., Ph.D., Chun-Xiang Fan, M.Sc., Gui-Jun Ning, M.Sc., Hong-Jie Yu, M.D., Shi-Wen Wang, M.D., Ph.D., Da-Wei Liu, M.D., Dong-Yan Wang, B.Sc., Jian-Ping Fu, M.D., Ai-li Gou, B.Sc., Guo-Min Zhang, Ph.D., Guo-Hong Huang, B.Sc., Yuan-Sheng Chen, M.D., Ph.D., Sha-Sha Mi, M.D., Yan-Min Liu, M.D., Da-Peng Yin, Ph.D., Hui Zhu, B.Sc., Xin-Chun Fan, B.Sc., Xin-Lan Li, B.Sc., Yi-Xin Ji, M.Sc., Ke-Li Li, M.D., Hai-Shu Tang, M.Sc., Wen-Bo Xu, M.D., Yu Wang, M.D., Ph.D., M.P.H, and Wei-Zhong Yang, M.D.
N Engl J Med 2013; 369:1981-1990November 21, 2013DOI: 10.1056/NEJMoa1303368

Background
The last case of infection with wild-type poliovirus indigenous to China was reported in 1994, and China was certified as a poliomyelitis-free region in 2000. In 2011, an outbreak of infection with imported wild-type poliovirus occurred in the province of Xinjiang.
Full Text of Background…

Methods
We conducted an investigation to guide the response to the outbreak, performed sequence analysis of the poliovirus type 1 capsid protein VP1 to determine the source, and carried out serologic and coverage surveys to assess the risk of viral propagation. Surveillance for acute flaccid paralysis was intensified to enhance case ascertainment.
Full Text of Methods…

Results
Between July 3 and October 9, 2011, investigators identified 21 cases of infection with wild-type poliovirus and 23 clinically compatible cases in southern Xinjiang. Wild-type poliovirus type 1 was isolated from 14 of 673 contacts of patients with acute flaccid paralysis (2.1%) and from 13 of 491 healthy persons who were not in contact with affected persons (2.6%). Sequence analysis implicated an imported wild-type poliovirus that originated in Pakistan as the cause of the outbreak. A public health emergency was declared in Xinjiang after the outbreak was confirmed. Surveillance for acute flaccid paralysis was enhanced, with daily reporting from all public and private hospitals. Five rounds of vaccination with live, attenuated oral poliovirus vaccine (OPV) were conducted among children and adults, and 43 million doses of OPV were administered. Trivalent OPV was used in three rounds, and monovalent OPV type 1 was used in two rounds. The outbreak was stopped 1.5 months after laboratory confirmation of the index case.
Full Text of Results…

Conclusions
The 2011 outbreak in China showed that poliomyelitis-free countries remain at risk for outbreaks while the poliovirus circulates anywhere in the world. Global eradication of poliomyelitis will benefit all countries, even those that are currently free of poliomyelitis.

Editorial: No Country Is Safe without Global Eradication of Poliomyelitis

New England Journal of Medicine
November 21, 2013  Vol. 369 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Editorial
No Country Is Safe without Global Eradication of Poliomyelitis
Trevor Mundel, M.D., Ph.D., and Walter A. Orenstein, M.D.
N Engl J Med 2013; 369:2045-2046November 21, 2013DOI: 10.1056/NEJMe131159
http://www.nejm.org/doi/full/10.1056/NEJMe1311591

In 1988, the World Health Assembly endorsed the goal of eradicating poliomyelitis worldwide. At the time, the estimated annual number of new cases of paralysis was 350,000, and poliomyelitis was considered to be endemic in 125 countries.1 In the 25 years since then, the incidence of poliomyelitis has been reduced by more than 99%, and only three countries — Pakistan, Nigeria, and Afghanistan — have never terminated indigenous transmission.1,2

Wild-type poliovirus type 2 has probably been eradicated; the last naturally occurring case was detected in 1999.2 Wild-type poliovirus type 3 appears to be close to eradication, with no new cases detected in 2013 (as of October 31, 2013).3-5 However, wild-type poliovirus type 1 remains in circulation.2,3 As illustrated by the 2011 poliomyelitis outbreak in China — a country that had not reported a case of paralysis caused by wild-type polioviruses since 1994 — as long as polioviruses circulate anywhere in the world, they can be exported to countries that are now poliomyelitis-free and can cause serious outbreaks.6

Public health authorities in China are to be commended for containing the outbreak so quickly. As described by Luo et al.6 in this issue of the Journal, a mass campaign to inoculate children with trivalent oral poliovirus vaccine was started within 3 weeks of outbreak confirmation, and the last case was detected approximately 1 month after the campaign was initiated. However, to make sure that polioviruses were truly eliminated, a total of five mass campaigns were conducted, in which 43.7 million doses of oral poliovirus vaccine were administered.6

The cost of containing the outbreak was considerable. Approximately $26 million (in U.S. dollars) was allocated for outbreak control. This cost does not include the less tangible cost of diverting hundreds of public health experts and local health workers from other important public health work. The apparently high immunity levels in this area of China probably made containment easier, since the population immunity was already close to herd-immunity thresholds.6

Should a similar outbreak occur in a poorer country with lower routine immunization coverage, or in a country that is not capable of responding as quickly, containment could prove far more difficult, as may be the case in the current importation of the poliovirus to the Horn of Africa and the Middle East, including Syria. Underscoring the highly infectious nature of poliomyelitis, importation of polioviruses from reservoir countries into areas that had been free of wild-type poliovirus has occurred in at least six countries so far this year, including Somalia (which had been free of the wild-type poliovirus since 2007), Kenya, Ethiopia, Syria, Cameroon, and Israel.3,7 The outbreak in the Horn of Africa was genetically traced to viruses from Nigeria, whereas the widespread circulation of wild-type poliovirus type 1 in Israel was linked to virus originating in Pakistan.7,8

To end poliomyelitis forever, the Global Polio Eradication Initiative (GPEI) has developed a comprehensive strategic plan to interrupt all transmission of wild-type poliovirus by the end of 2014 and to certify the world as poliomyelitis-free by 2018.2 Global eradication will require several key actions; these include administering oral poliovirus vaccine to interrupt the transmission of wild-type polioviruses, building and sustaining political commitment, improving routine immunization delivery in remaining reservoir countries, delivering vaccines to children living in areas in conflict, and providing rigorous, ongoing oversight.

One essential part of the plan was to replace the current trivalent oral poliovirus vaccine with a bivalent vaccine containing only virus types 1 and 3. Oral poliovirus vaccine has been the major vaccine used in the eradication program because it is easy to administer, can passively immunize persons who do receive the vaccine directly, is relatively inexpensive, and induces greater intestinal immunity than that conferred by inactivated poliovirus vaccine. This superior intestinal immunity should be more effective in decreasing transmission, since in the developing world most poliovirus is thought to be spread by the fecal–oral route. However, on rare occasions, oral poliovirus vaccine has been known to cause paralysis, either as a result of vaccine-associated paralytic polio or by means of circulating vaccine-derived polioviruses that have acquired some properties of wild viruses.3,9 Removing type 2 oral poliovirus vaccine should reduce vaccine-associated paralytic polio and cases of circulating vaccine-derived poliovirus infection by about 40% and more than 95%, respectively.3,9

A further benefit of the bivalent oral poliovirus vaccine (as compared with the trivalent vaccine) is that it would enhance immunogenicity against types 1 and 3 poliovirus.10 To maintain population immunity to the type 2 virus and to reduce the risk of outbreaks of type 2 if it were reintroduced (e.g., through a break in laboratory containment), the administration of at least one dose of inactivated poliovirus is recommended in routine immunization.11

The estimated cost of the 2013–2018 GPEI strategic plan is approximately $5.5 billion.2 This is clearly a substantial investment, but the failure to achieve global eradication would cost far more. Mathematical models suggest that abandoning the program before eradication is achieved would result in a massive resurgence of poliomyelitis, with approximately 200,000 cases of paralysis annually.12 In addition to the huge financial burden this would impose — particularly in countries in the developing world — the human costs of a resurgence of poliomyelitis are incalculable.

The history of successful eradication efforts over more than two decades has proven that we can finish the job. The real lesson of the outbreak in China is that if we do not, any country is vulnerable to reimportation of poliomyelitis. Without question, the best defense against poliovirus is a good offense that eliminates the virus from the remaining reservoirs and truly eradicates the disease.

Vaccine-Preventable Disease Among Homeschooled Children: Two Cases of Tetanus in Oklahoma

Pediatrics
November 2013, VOLUME 132 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml
[Reviewed earlier]

Online
Case Report
Vaccine-Preventable Disease Among Homeschooled Children: Two Cases of Tetanus in Oklahoma
Matthew G. Johnson, MDa, Kristy K. Bradley, DVMb, Susan Mendus, MPHc, Laurence Burnsed, MPHd, Rachel Clinton, MSd, and Tejpratap Tiwari, MDe

Abstract
Homeschooled children represent an increasing proportion of school-aged children in the United States. Immunization rates among homeschooled children are largely unknown because they are usually not subject to state-based school-entry vaccination requirements. Geographic foci of underimmunized children can increase the risk for outbreaks of vaccine-preventable diseases. In 2012, 2 cases of tetanus were reported in Oklahoma; both cases involved homeschooled children without documentation of diphtheria-tetanus-acellular pertussis vaccination. We describe the characteristics of both patients and outline innovative outreach measures with the potential to increase vaccination access and coverage among homeschooled children.

Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data

PLoS Medicine
(Accessed 23 November 2013)
http://www.plosmedicine.org/

Research Article
Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data
Hongjie Yu, Wladimir J. Alonso, Luzhao Feng, Yi Tan, Yuelong Shu, Weizhong Yang, Cécile Viboud
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001552
Abstract
Background
The complexity of influenza seasonal patterns in the inter-tropical zone impedes the establishment of effective routine immunization programs. China is a climatologically and economically diverse country, which has yet to establish a national influenza vaccination program. Here we characterize the diversity of influenza seasonality in China and make recommendations to guide future vaccination programs.

Methods and Findings
We compiled weekly reports of laboratory-confirmed influenza A and B infections from sentinel hospitals in cities representing 30 Chinese provinces, 2005–2011, and data on population demographics, mobility patterns, socio-economic, and climate factors. We applied linear regression models with harmonic terms to estimate influenza seasonal characteristics, including the amplitude of annual and semi-annual periodicities, their ratio, and peak timing. Hierarchical Bayesian modeling and hierarchical clustering were used to identify predictors of influenza seasonal characteristics and define epidemiologically-relevant regions. The annual periodicity of influenza A epidemics increased with latitude (mean amplitude of annual cycle standardized by mean incidence, 140% [95% CI 128%-151%] in the north versus 37% [95% CI 27%-47%] in the south, p<0.0001). Epidemics peaked in January–February in Northern China (latitude ≥33°N) and April–June in southernmost regions (latitude <27°N). Provinces at intermediate latitudes experienced dominant semi-annual influenza A periodicity with peaks in January–February and June–August (periodicity ratio >0.6 in provinces located within 27.4°N-31.3°N, slope of latitudinal gradient with latitude -0.016 [95% CI -0.025 to -0.008], p<0.001). In contrast, influenza B activity predominated in colder months throughout most of China. Climate factors were the strongest predictors of influenza seasonality, including minimum temperature, hours of sunshine, and maximum rainfall. Our main study limitations include a short surveillance period and sparse influenza sampling in some of the southern provinces.

Conclusions
Regional-specific influenza vaccination strategies would be optimal in China; in particular, annual campaigns should be initiated 4–6 months apart in Northern and Southern China. Influenza surveillance should be strengthened in mid-latitude provinces, given the complexity of seasonal patterns in this region. More broadly, our findings are consistent with the role of climatic factors on influenza transmission dynamics.

Editors’ Summary
Background
Every year, millions of people worldwide catch influenza, a viral disease of the airways. Most infected individuals recover quickly but seasonal influenza outbreaks (epidemics) kill about half a million people annually. These epidemics occur because antigenic drift—frequent small changes in the viral proteins to which the immune system responds—means that an immune response produced one year provides only partial protection against influenza the next year. Annual vaccination with a mixture of killed influenza viruses of the major circulating strains boosts this natural immunity and greatly reduces the risk of catching influenza. Consequently, many countries run seasonal influenza vaccination programs. Because the immune response induced by vaccination decays within 4–8 months of vaccination and because of antigenic drift, it is important that these programs are initiated only a few weeks before the onset of local influenza activity. Thus, vaccination starts in early autumn in temperate zones (regions of the world that have a mild climate, part way between a tropical and a polar climate), because seasonal influenza outbreaks occur in the winter months when low humidity and low temperatures favor the transmission of the influenza virus.

Why Was This Study Done?
Unlike temperate regions, seasonal influenza patterns are very diverse in tropical countries, which lie between latitudes 23.5°N and 23.5°S, and in the subtropical countries slightly north and south of these latitudes. In some of these countries, there is year-round influenza activity, in others influenza epidemics occur annually or semi-annually (twice yearly). This complexity, which is perhaps driven by rainfall fluctuations, complicates the establishment of effective routine immunization programs in tropical and subtropical countries. Take China as an example. Before a national influenza vaccination program can be established in this large, climatologically diverse country, public-health experts need a clear picture of influenza seasonality across the country. Here, the researchers use spatio-temporal modeling of influenza surveillance data to characterize the seasonality of influenza A and B (the two types of influenza that usually cause epidemics) in China, to assess the role of putative drivers of seasonality, and to identify broad epidemiological regions (areas with specific patterns of disease) that could be used as a basis to optimize the timing of future Chinese vaccination programs.

What Did the Researchers Do and Find?
The researchers collected together the weekly reports of laboratory-confirmed influenza prepared by the Chinese national sentinel hospital-based surveillance network between 2005 and 2011, data on population size and density, mobility patterns, and socio-economic factors, and daily meteorological data for the cities participating in the surveillance network. They then used various statistical modeling approaches to estimate influenza seasonal characteristics, to assess predictors of influenza seasonal characteristics, and to identify epidemiologically relevant regions. These analyses indicate that, over the study period, northern provinces (latitudes greater than 33°N) experienced winter epidemics of influenza A in January–February, southern provinces (latitudes less than 27°N) experienced peak viral activity in the spring (April–June), and provinces at intermediate latitudes experienced semi-annual epidemic cycles with infection peaks in January–February and June–August. By contrast, influenza B activity predominated in the colder months throughout China. The researchers also report that minimum temperatures, hours of sunshine, and maximum rainfall were the strongest predictors of influenza seasonality.

What Do These Findings Mean?
These findings show that influenza seasonality in China varies between regions and between influenza virus types and suggest that, as in other settings, some of these variations might be associated with specific climatic factors. The accuracy of these findings is limited by the short surveillance period, by sparse surveillance data from some southern and mid-latitude provinces, and by some aspects of the modeling approach used in the study. Further surveillance studies need to be undertaken to confirm influenza seasonality patterns in China. Overall, these findings suggest that, to optimize routine influenza vaccination in China, it will be necessary to stagger the timing of vaccination over three broad geographical regions. More generally, given that there is growing interest in rolling out national influenza immunization programs in low- and middle-income countries, these findings highlight the importance of ensuring that vaccination strategies are optimized by taking into account local disease patterns.

.
Perspective
Complex Disease Dynamics and the Design of Influenza Vaccination Programs
Steven Riley
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001553

For influenza vaccine programs to be optimal from the point of view of the individual at risk of infection, two conditions must be met. First, the vaccine must contain antigens that are well-matched to currently circulating strains [1]. Second, the vaccine must be administered at the right time: early enough that there is sufficient time for antibodies to rise in response to the vaccination, but not so early that protection by the vaccine wanes prior to infectious challenge [2]. The rate of waning of vaccine-induced protection against influenza is particularly high for older adults, one of the groups most at-risk of severe outcomes and often a top priority for national vaccination programs. Therefore, good knowledge of likely temporal trends in the risk of influenza infection is a necessary prerequisite for the design of optimal vaccination programs.

In this week’s PLOS Medicine, Cécile Viboud and colleagues [3] present an extensive analysis of sentinel virological surveillance of influenzas A(H3N2) and B from China with the objective of finding epidemiological patterns that support the design of the country’s first national influenza vaccination program. The authors use time series of viral isolation data from a network of sentinel hospitals, finding strong evidence for key epidemiological features of the incidence of influenza subtypes. Rather than relying on syndromic definitions or excess mortality, these biologically robust outcomes identify the patterns of circulating strains with high specificity.    Despite variability in both the propensity of individuals to seek treatment and the likelihood of them being tested, virological surveillance data accurately describe the timing of peak incidence, the duration of elevated incidence (the influenza season), and periods when influenza is absent (provided testing levels are high year-round).

In many temperate populations such as the United States, knowledge of epidemiological patterns of influenza incidence has facilitated the robust design of vaccination programs [4]: incidence is strongly seasonal, with a very low risk of infection during the summer. The vast majority of infections are focused in a 6–8 week period in the winter months. Therefore, vaccination programs that are expected to last ~6 weeks are initiated ~12 weeks prior to the expected start of the season (the beginning of October in the Northern Hemisphere and the beginning of April in the Southern Hemisphere).

At lower latitudes, patterns are far less clear [5]. Equatorial populations such as Singapore report almost constant year-round incidence of influenza-like illness [6], while some subtropical locations, such as Hong Kong, exhibit weak biennial cycles, with their seasonality characterized primarily by a clear off-season [7]. A study of influenza patterns in Brazil, a country with a large population spanning a wide range of latitudes, revealed wave-like dynamics originating in the less populated equatorial region and travelling out towards larger temperate populations (based on excess pneumonia and influenza mortality) [8].

In their study, Viboud and colleagues were able to separate China into three epidemiological zones for influenza A(H3N2). In the temperate north, incidence peaked sharply during January and February, while in the tropical south, a longer epidemic with a lower peak was observed during April and May. The regions in the middle latitudinal zone exhibited biannual cycles with smaller incidence peaks temporally aligned with their northern and the southern neighbors.

Intriguingly, there were clear differences in the spatial patterns of influenza B compared with those of influenza A. There was little evidence of biannual cycles for influenza B, with the timing of the single peak each year closely correlated with latitude: epidemics occurred first in the north and then progressed steadily to the south. Perhaps most striking, the authors also found that the proportion of samples positive for influenza B increased from less than 20% in the northernmost provinces to almost 50% in the southernmost provinces. These observations point to fundamentally different circulation patterns between influenzas A(H3N2) and B and should motivate systematic phylogeographical and serotype studies of influenza B at the national scale in China.

The observed differences in circulation patterns between influenzas A(H3N2) and B present challenges for the design of vaccination programs at middle and lower latitudes in China. As the authors observe, the timing of peaks in the southernmost provinces is only marginally ahead of Southern Hemisphere populations and suggests that those provinces may wish to follow the Southern Hemisphere timetable. However, such a decision might be slightly premature: genetic data from even a small subset of the viral isolates used for this study could give a definitive picture of the ancestral relationship between viruses circulating in southern China relative to viruses in northern China and Southern Hemisphere populations.

A lasting legacy of the 2009 pandemic is increased interest in novel methods of manufacture for influenza vaccines [9]. Although the vast majority of vaccines delivered today arise from egg-based production systems (not substantially different from those used for the first vaccine trials approx 70 years ago), there are a number of alternative production processes under investigation that may reduce both costs and timelines [10],[11],[12]. When these technologies are fully developed, they could greatly facilitate the redesign of vaccination programs for both seasonal and pandemic influenza. As epidemiological and phylogenetic studies reveal more about the circulation of specific influenza virus subtypes in different regions of the world, it seems likely that the current system of selecting only two official vaccine strain sets per year will be refined. The results presented by Viboud and colleagues [3] suggest that rapidly expanding vaccination programs in populous mid-latitude provinces of China may provide an ideal setting in which to investigate the possible benefits of rapid vaccine production and locally-informed strain selection.

NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landsca

PLoS Neglected Tropical Diseases
November 2013
http://www.plosntds.org/article/browseIssue.action

Viewpoints
NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape
Peter J. Hotez
Abstract
The concept of the neglected tropical diseases (NTDs) was established in the aftermath of the Millennium Development Goals. Here, we summarize the emergence of several new post-2010 global health documents and policies, and how they may alter the way we frame the world’s major NTDs since they were first highlighted. These documents include a new Global Burden of Disease 2010 Study that identifies visceral leishmaniasis and food-borne trematode infections as priority diseases beyond the seven NTDs originally targeted by preventive chemotherapy, a London Declaration for access to essential medicines, and a 2013 World Health Assembly resolution on NTDs. Additional information highlights an emerging dengue fever pandemic. New United Nations resolutions on women and the non-communicable diseases (NCDs) have not yet embraced NTDs, which may actually be the most common afflictions of girls and women and represent a stealth cause of NCDs. NTDs also have important direct and collateral effects on HIV/AIDS and malaria, and there is now a robust evidence base and rationale for incorporating NTDs into the Global Fund to Fight AIDS, Tuberculosis, and Malaria. “Blue marble health” is an added concept that recognizes a paradoxical NTD disease burden among the poor living in G20 (Group of Twenty) and other wealthy countries, requiring these nations to take greater ownership for both disease control and research and development. As we advance past the year 2015, it will be essential to incorporate global NTD elimination into newly proposed Sustainable Development Goals.

Cholera Vaccination Campaign Contributes to Improved Knowledge Regarding Cholera and Improved Practice Relevant to Waterborne Disease in Rural Hait

PLoS Neglected Tropical Diseases
November 2013
http://www.plosntds.org/article/browseIssue.action

Research Article
Cholera Vaccination Campaign Contributes to Improved Knowledge Regarding Cholera and Improved Practice Relevant to Waterborne Disease in Rural Haiti
Omowunmi Aibana, Molly Franke, Jessica Teng, Johanne Hilaire, Max Raymond, Louise C. Ivers

Background
Haiti’s cholera epidemic has been devastating partly due to underlying weak infrastructure and limited clean water and sanitation. A comprehensive approach to cholera control is crucial, yet some have argued that oral cholera vaccination (OCV) might result in reduced hygiene practice among recipients. We evaluated the impact of an OCV campaign on knowledge and health practice in rural Haiti.

Methodology/Principal Findings
We administered baseline surveys on knowledge and practice relevant to cholera and waterborne disease to every 10th household during a census in rural Haiti in February 2012 (N = 811). An OCV campaign occurred from May–June 2012 after which we administered identical surveys to 518 households randomly chosen from the same region in September 2012. We compared responses pre- and post-OCV campaign. Post-vaccination, there was improved knowledge with significant increase in percentage of respondents with ≥3 correct responses on cholera transmission mechanisms (odds ratio[OR] 1.91; 95% confidence interval[CI] 1.52-2.40), preventive methods (OR 1.83; 95% CI 1.46-2.30), and water treatment modalities (OR 2.75; 95% CI 2.16-3.50). Relative to pre-vaccination, participants were more likely post-OCV to report always treating water (OR 1.62; 95% CI 1.28-2.05). Respondents were also more likely to report hand washing with soap and water >4 times daily post-vaccine (OR 1.30; 95% CI 1.03-1.64). Knowledge of treating water as a cholera prevention measure was associated with practice of always treating water (OR 1.47; 95% CI 1.14-1.89). Post-vaccination, knowledge was associated with frequent hand washing (OR 2.47; 95% CI 1.35-4.51).

Conclusion
An OCV campaign in rural Haiti was associated with significant improvement in cholera knowledge and practices related to waterborne disease. OCV can be part of comprehensive cholera control and reinforce, not detract from, other control efforts in Haiti.

Justice in Global Pandemic Influenza Preparedness: An Analysis Based on the Values of Contribution, Ownership and Reciprocity [Indonesia]

Public Health Ethics
Volume 6 Issue 3 November 2013
http://phe.oxfordjournals.org/content/current

Justice in Global Pandemic Influenza Preparedness: An Analysis Based on the Values of Contribution, Ownership and Reciprocity
Meena Krishnamurthy, Matthew Herder
http://phe.oxfordjournals.org/content/6/3/272.abstract

Abstract
In December 2006, Indonesia decided to stop sending influenza virus specimens to the World Health Organization’s Global Influenza Surveillance Network (GISN). Indonesia justified its actions by claiming that they were in protest of the injustice of GISN. Its actions stimulated negotiations to improve the workings of GISN by developing and implementing a more just framework for ‘sharing influenza viruses and other benefits’. These negotiations eventually led to the adoption of a new framework for virus and benefit sharing in May 2011, at the World Health Assembly meeting. In this article, we critically evaluate Indonesia’s claims about the unjustness of GISN. We show that arguments based on the values of ownership, contribution and reciprocity work together to support Indonesia’s claim that it was owed an equal share in the benefits of GISN and, in turn, that GISN was unjust because of its failure to ensure this. We also use these values to evaluate the newly agreed upon framework for virus and benefit sharing. We suggest the new framework fails to give proper consideration to the values of ownership, contribution and reciprocity and, as a result, that it is fundamentally unjust.

From Google Scholar+ [to 23 November 2013]

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine
A Cómbita, D Duarte, J Rodríguez, M Molano… – Revista Colombiana de …, 2013
Objective To analyze whether the immune response to HPV-16,-18,-31,-45 and-58 capsids in women vaccinated with the quadrivalent vaccine induces cross-reactivity against other HPV virus-like particles (VLPs). Methods A total of 88 women aged between 18 and 27 …

[PDF] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
MT Herrera, Y Gonzalez, E Juárez… – BMC Infectious Diseases, 2013
Background The efficacy of the H1N1 influenza vaccine relies on the induction of both humoral and cellular responses. This study evaluated the humoral and cellular responses to a monovalent non-adjuvanted pandemic influenza A/H1N1 vaccine in occupationally …

BASHH and the media [British Association for Sexual Health and HIV]
P Greenhouse, N Balmer, R Patel – Sexually Transmitted Infections, 2013
… This is probably best demonstrated by the media activity undertaken by BASHH around the human papillomavirus (HPV) vaccine, which is described in more detail below. Primarily, public education is a core function of the group. …

Special Focus Newsletters
RotaFlash – Rotavirus Vaccine Update   PATH 21 November 2013
Headline: Unanticipated benefits of rotavirus vaccination in the United States
http://vad.createsend4.com/t/ViewEmail/r/F18B988AE89914842540EF23F30FEDED/E38B11B8894CC5F5DBC23BD704D2542D

New York Times Editorial: Responding to a Meningitis Outbreak (Princeton University)

New York Times
http://www.nytimes.com/
Accessed 23 November 2013

Editorial
Responding to a Meningitis Outbreak
By THE EDITORIAL BOARD
Published: November 22, 2013

A vaccine approved for use in Europe and Australia but not in the United States will be imported to help quell an outbreak of bacterial meningitis at Princeton University. This is a good example of how two federal agencies — the Centers for Disease Control and Prevention and the Food and Drug Administration — can collaborate to reach a common-sense solution to protect the public’s health.

The university has been experiencing a small and slow-moving outbreak of a type of bacterial meningitis known as strain B. Four students and a visitor to the campus developed symptoms between March 22 and June 29; all have recovered. Two other students developed symptoms in October and early November. One has recovered; the other is recovering. On Friday, another student was diagnosed with meningitis, and tests are underway to determine whether it was caused by strain B.

Last year, some 160 cases of strain B were reported in the United States. The disease can cause headaches, high fevers and stiff necks, and it is fatal in 10 percent to 15 percent of the cases.

The vaccine currently used to prevent bacterial meningitis in this country protects against several other strains but not against strain B. The only vaccine proved to be effective against strain B is Bexsero, made by Novartis, which is based in Switzerland and which won regulatory approval for the vaccine in Europe in January and in Australia in August. The company has not pushed for approval here because it is concentrating on a vaccine against the other strains.

In this case, the C.D.C. requested permission to import the vaccine, and the F.D.A. approved it through a limited special process used occasionally to handle emergency situations, such as a shortage of critically needed cancer drugs last year. The vaccine will be available to all Princeton undergraduates starting next month, as well as to graduate students who live in dormitories and to people affiliated with the university who have specific medical conditions that put them at risk.

Although the imported vaccine has been approved only for use at Princeton, the C.D.C. should apply to have Bexsero available if a similar outbreak occurs somewhere else, and the F.D.A. should grant such approval.

Vaccines and Global Health: The Week in Review 16 Nov 2013

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_16 Nov 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

WHO responding to health needs caused by typhoon Haiyan (Yolanda) 201

WHO – Humanitarian Health Action
http://www.who.int/hac/en/index.html

WHO responding to health needs caused by typhoon Haiyan (Yolanda) 2013
15 November 2013 Super typhoon Yolanda (Haiyan) hit the Philippines on 8 November 2013. Storm surges caused widespread flooding in coastal areas and brought damages to 44 provinces, in many Regions in Central Philippines. The most severely affected areas identified so far are Tacloban City, Leyte, Northern Iloilo and Eastern Samar. Health services in affected areas are completely hampered. Health priorities include injury management, preventing the spread of communicable diseases, maternal and child health services and mental health and psychosocial support.
:: Situation report 15 November 2013
pdf, 887kb

:: Read the latest WHO press release – 13 November 2013
:: Read the WHO donor alert – 10 November 2013
pdf, 279kb

:: DSWD Disaster mitigation and response situation map
http://www.who.int/hac/en/index.html

WHO SAGE: Vaccination in acute humanitarian emergencies – a framework for decision making

WHO SAGE: Vaccination in acute humanitarian emergencies – a framework for decision making
WHO/IVB/13.07  October 2013
Excerpt
From Executive Summary
1.3 Conclusion
This document provides key decision-makers in the national ministries of health and international partner agencies with a systematic and comprehensive approach to
decision-making on the use of vaccines in acute humanitarian emergencies, and it also provides guidance on ethical concerns such as prioritization of interventions, targeting of high-risk groups, equity and informed consent. It is hoped that this document will make a useful contribution to optimal management of vaccine- preventable diseases in acute humanitarian emergences and ultimately to reduction in preventable morbidity and mortality commonly associated with acute humanitarian emergencies.

[Jointly developed and published by the departments of Emergency Risk Management and Humanitarian Response (ERM); Immunization, Vaccines and Biologicals (IVB); and Pandemic and Epidemic Diseases (PED). This document was prepared by the Strategic Advisory Group of Experts on Immunization (SAGE) Working Group on Vaccination in Humanitarian Emergencies (http://www.who.int/immunization/sage/sage_wg_hum_emergencies_jun11/en/ under the oversight of SAGE and was endorsed by SAGE at its November 2012 meeting
http://www.who.int/wer/2013/wer8801.pdf
pdf download: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CCsQFjAA&url=http%3A%2F%2Fwww.who.int%2Firis%2Fbitstream%2F10665%2F92462%2F1%2FWHO_IVB_13.07_eng.pdf&ei=fuWHUrrANrW44AOs1IAQ&usg=AFQjCNFY-3dG0Z2zsVMbO1tzRYsxKLjlIg&bvm=bv.56643336,d.dmg

Polio Watch [to 16 November 2013]

UN Watch to 16 November 2013
Selected meetings, press releases, and press conferences relevant to immunization, vaccines, infectious diseases, global health, etc. http://www.un.org/en/unpress/
UN: Press Conference by Office for Coordination of Humanitarian Affairs on Sudan Polio Vaccinations, Philippines Super Typhoon Haiyan
11 November 2013
Excerpt [Editor’s bolding]
The Security Council should “unlock” the situation in Sudan’s South Kordofan and Blue Nile States so that humanitarian agencies and partners could have unfettered access to administer polio vaccinations in the two States, a senior official from the Office for the Coordination of Humanitarian Affairs said at a Headquarters press conference today.

John Ging, Director of Operations, who had earlier updated the Security Council on the planned vaccination, stated that, because of a lack of access, humanitarian agencies had been unable to deal with the outbreak of polio in the region, thus failing to save thousands of children and provide relief assistance to those in need.

He recalled that over a year ago, the Council, in resolution 2046 (2012), had called for unfettered access for humanitarian agencies and partners.  Yet, nothing had changed.  The vaccination campaign, aimed to cover 165,000 children and ensure Sudan be polio free, was hindered by the impasse between the Government of Sudan and the Sudan People’s Liberation Movement-North (SPLM-N) controlled areas of South Kordofan and Blue Nile.

“Although, the Government of Sudan announced a window of opportunity for the vaccination, which expired today, however, SPLM-North was insisting on meetings before the polio campaign, and the Government, on its part, said no to the discussions, so there was an impasse,” Mr. Ging stated.

He appealed to the Council to re-engage with the parties for humanitarian access and to facilitate the vaccination programme, underscoring that the Office for the Coordination of Humanitarian Affairs and its partners were ready with both human resources and supplies to undertake the programme.

“If we get the green light, we, on the United Nations side, are ready and it will only take four days to vaccinate the children,” he added.

Mr. Ging also said the World Health Organization (WHO) and United Nations Children’s Fund (UNICEF) were working in collaboration with local health authorities in Sudan for the polio vaccination and the distribution other medical requirements, as well…
http://www.un.org/News/briefings/docs//2013/131111_Guest.doc.htm

WHO: Update on polio outbreak in Middle East
WHO statement
13 November 2013
Excerpt [Editor’s bolding]
A comprehensive outbreak response continues to roll out across the Middle East following confirmation of the polio outbreak in Syria.

Seven countries and territories are holding mass polio vaccination campaigns with further extensive campaigns planned for December targeting 22 million children. In a joint resolution all countries of the WHO Eastern Mediterranean Region have declared polio eradication to be an emergency and called on Pakistan to urgently access and vaccinate all of its children to stem the international spread of its viruses. The countries also called for support in negotiating and establishing access to those children who are currently unreached with polio vaccination.

WHO and UNICEF are committed to working with all organizations and agencies providing humanitarian assistance to Syrians affected by the conflict. This includes vaccinating all Syrian children no matter where they are, whether in government or contested areas, or indeed outside Syria.

The first priorities are to resupply and reactivate the required health infrastructure, including redeploying health workers to deliver vaccine in worst-affected areas, and moving vaccine across conflict lines where necessary and possible. The government has committed to reach all children; information on which areas are not reached will guide corrective actions and planning for the next rounds. All parties are working to find solutions for conflict-affected areas…

Larger-scale outbreak response across the Syrian Arab Republic and neighboring countries will continue, to last for at least 6 to 8 months depending on the area and based on evolving epidemiology.
http://www.who.int/mediacentre/news/statements/2013/polio-syria-20131113/en/index.html

UNHCR: Teams working to fight the expansion of polio in Syria
Press Release: 13 November 2013
Excerpt
The UN refugee agency (UNHCR) is working to help address polio vaccination needs inside Syria’s hard-to-reach zones in close coordination with the Syrian Arab Red Crescent as the two relief agencies have joined with other agencies to participate in the national polio vaccination campaign that began recently following reports of several polio cases.

UNHCR and the Syrian Arab Red Crescent (SARC) are working together to support the vaccination campaign in areas that are usually hard to reach in Rural Damascus, Rural Homs, Deir Ezzor and Raqqa…

…So far, throughout Al Hassakeh province, 87,728 children have been vaccinated including 7,676 children who were vaccinated by the UNHCR-supported volunteers. Next week UNHCR’s volunteers will join mobile teams to access children in remote areas.

…Meanwhile, UNHCR continues to participate in the awareness campaign highlighting issues surrounding polio and measles. Awareness campaigns are a proven means to reaching vulnerable young Syrian children who may have missed vital vaccinations…

WHO: Global Alert and Response (GAR) – Disease Outbreak News
http://www.who.int/csr/don/2013_03_12/en/index.html
:: Cholera in Mexico – update 13 November 2013
:: Middle East respiratory syndrome coronavirus (MERS-CoV) – update 11 November 2013
:: Middle East respiratory syndrome coronavirus (MERS-CoV) – update 10 November 2013
:: Polio in the Syrian Arab Republic – update 11 November 2013
Thirteen cases of wild poliovirus type 1 (WPV1) have been confirmed in the Syrian Arab Republic. Genetic sequencing indicates that the isolated viruses are most closely linked to virus detected in environmental samples in Egypt in December 2012 (which in turn had been linked to wild poliovirus circulating in Pakistan). Closely related wild poliovirus strains have also been detected in environmental samples in Israel, West Bank and Gaza Strip since February 2013. Wild poliovirus had not been detected in the Syrian Arab Republic since 1999.

A comprehensive outbreak response continues to be implemented across the region. On 24 October 2013, an already-planned large-scale supplementary immunization activity was launched in the Syrian Arab Republic to vaccinate 1.6 million children against polio, measles, mumps and rubella, in both government-controlled and contested areas. Implementation of a supplementary immunization campaign in Deir Al Zour province commenced promptly when the first ‘hot’ acute flaccid paralysis (AFP) cases were reported. Larger-scale outbreak response across the Syrian Arab Republic and neighbouring countries will continue for at least 6-8 months depending on the area and based on the evolving situation.

Given the current situation in the Syrian Arab Republic, frequent population movements across the region and the immunization level in key areas, the risk of further international spread of wild poliovirus type 1 across the region is considered to be high. A surveillance alert has been issued for the region to actively search for additional potential cases.

WHO’s International Travel and Health recommends that all travellers to and from polio-infected areas be fully vaccinated against polio.
http://www.who.int/csr/don/2013_11_11polio/en/index.html

Update: Polio this week – As of 6 November 2013
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
[Editor’s extract and bolded text]
:: Thirteen cases of wild poliovirus type 1 (WPV1) have been confirmed in the Syrian Arab Republic. Genetic sequencing indicates that the isolated viruses are most closely linked to virus detected in environmental samples in Egypt in December 2012 (which in turn had been linked to wild poliovirus circulating in Pakistan). Closely related wild poliovirus strains have also been detected in environmental samples in Israel, and The West Bank and Gaza Strip since February 2013. A comprehensive outbreak response continues to be implemented across the sub-region. [see above]
:: The number of WPV1 cases in Pakistan for 2013 (59) now exceeds the number of polio cases reported from Pakistan during the same time period in 2012 (54). Nigeria has reported half the cases (51/101) and Afghanistan one third (9/27) of cases compared to the same time period in 2012.
Pakistan
:: Three new WPV1 cases were reported in the past week – two from Toba Tek Singh district in Punjab and one from North Waziristan in the Federally Administered Tribal Areas (FATA).
:: The total number of WPV1 cases for Pakistan in 2013 is now 59. The most recent WPV1 case had onset of paralysis on 21 October (from Toba Tek Singh district, Punjab). The majority of WPV1 cases in Pakistan this year, 41 (69%), are from FATA, of which 16 are from Khyber Agency and 18 from North Waziristan.
:: Three new cVDPV2 cases were reported in the past week, all from North Waziristan. The total number of cVDPV2 cases for Pakistan is now 35. The most recent cVDPV2 case had onset of paralysis 15 October (from North Waziristan).
:: The situation in North Waziristan is increasingly alarming. It is the area with the largest number of children being paralyzed by poliovirus in all of Asia (18 WPV1 and 28 cVDPV2 cases).  Immunization activities have been suspended by local leaders since June 2012. It is critical that children in these areas are vaccinated and protected from poliovirus. Immunizations in neighboring high-risk areas are being intensified, to further boost population immunity levels in those areas and prevent further spread of this outbreak.
Chad, Cameroon and Central African Republic
:: In Cameroon, a second WPV1 case was reported in the past week from Foumbot, Ouest region, following the first WPV1 case reported from Ouest region with onset of paralysis on 19 October 2013. Outbreak response is underway.
Syrian Arab Republic
:: Three new WPV1 cases were reported from Deir-Al-Zour governorate in the past week. The total number of WPV1 cases for Syria in 2013 is now 13, all from Deir-Al-Zour. Wild poliovirus was last reported in Syria in 1999.
:: A comprehensive outbreak response continues to be implemented in Syria and across the sub-region. On 24 October 2013, an already-planned large-scale supplementary immunization activity was launched in the Syrian Arab Republic to vaccinate 1.6 million children against polio, measles, mumps and rubella, in both government-controlled and contested areas.
:: Implementation of a supplementary immunization campaign in Deir-Al-Zour province commenced promptly when the first ‘hot’ acute flaccid paralysis (AFP) cases were reported.
:: Larger-scale outbreak response SIAs across the Syrian Arab Republic and neighbouring countries will continue for at least 6-8 months depending on the area and based on the evolving epidemiological situation. The main aim is to rapidly reach children in the immediately-affected and other high-risk areas, followed by wider-scale immunization campaigns across the region targeting 22 million children over the next 6 months.

Associated Press: Nigeria pays families of slain polio workers
November 14, 2013 1:47 PM
KANO (AP) — The Nigerian government gave nearly $200,000 (30 million Naira) to families of slain polio vaccinators Thursday, after rights groups across the country called for reparations for victims of suspected Islamic militants.

The 10 health workers were killed in February as they were preparing to visit homes in the northern city of Kano to vaccinate children for polio. The family of each victim was given a check for 3 million Naira.

Islamic extremists in northern Nigeria often preach against polio vaccinations, saying they are part of a Western plot to sterilize Muslims.

After four years of insurgency in northern Nigeria, activists last week threatened to sue the government under international human rights treaties for compensation for victims.
http://news.yahoo.com/nigeria-pays-families-slain-polio-workers-184751898.html

Fifth Annual World Pneumonia Day Marks Successes and Challenges

Fifth Annual World Pneumonia Day Marks Successes and Challenges in Tackling #1 Killer of Children
Global Coalition Against Child Pneumonia Calls for Continued Investment in Innovations and Proven Tools

(BALTIMORE, MARYLAND) — Global health advocates today commemorated the fifth annual World Pneumonia Day by calling on global leaders to scale up existing interventions and invest in new diagnostics and treatments to defeat pneumonia. Each year, pneumonia kills more children than AIDS, malaria and tuberculosis combined. Pneumonia took the lives of nearly 1.1 million children under 5 in 2012 alone, with more than 99 percent of these deaths in developing countries, where access to healthcare facilities and treatment is out of reach for many children…

World Pneumonia Day was established in 2009 to raise awareness about pneumonia; to promote interventions to protect against, prevent, and treat pneumonia; and to generate action in combating pneumonia. For more information about World Pneumonia Day and its activities, please visit www.worldpneumoniaday.org.
http://worldpneumoniaday.org/fifth-annual-world-pneumonia-day-marks-successes-and-challenges/

The International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health released today its 2013 Pneumonia and Diarrhoea Progress Report, which found gradual increases in access to vaccines, treatment, and other interventions in the 15 countries with the highest numbers of child deaths from pneumonia and diarrhoea. The report found that seven countries achieved some progress toward the GAPPD targets, while eight countries had not made significant progress toward reaching targets.

WHO: 2013 Malaria Vaccine Technology Roadmap

WHO: 2013 Malaria Vaccine Technology Roadmap
Malaria Vaccine Technology Roadmap
pdf, 2.01Mb

14 November 2013
[Full text]
The updated Malaria Vaccine Roadmap represents the result of a review process facilitated by the World Health Organization (WHO), which worked with the Malaria Vaccine Funders Group to update the vision and strategic goals of the first publication. Originally launched at the 2006 WHO Global Vaccine Research Forum and supported by the Funders Group, the Roadmap forms a strategic framework that underpins the activities of the global malaria vaccine research and development (R&D) community.

This update responds to the recognition that the malaria epidemiological and control status has changed markedly since 2006 when the Roadmap was originally launched. For instance, substantial changes in malaria epidemiology are now being observed in many settings following a reduction in malaria transmission, which has occurred in association with the scale-up of malaria control measures. The reduction in malaria transmission is associated with a shift in the peak age of clinical malaria to older children, as well as an increase in the median age of malaria-related hospitalization in some settings. In response to these developments and acknowledging substantial changes in the strategic direction for malaria research, the shared vision and strategic goals of the Roadmap have been expanded.

The vision and goals now encompass the current ambitious aims of the global malaria community, which include prevention of malaria disease and deaths, accompanied by the accepted goals of progressive malaria elimination and—ultimately— global eradication. In addition, the revision includes the need to address Plasmodium vivax malaria infections (in contrast to Plasmodium falciparum alone), all malaria-endemic areas (in contrast to sub-Saharan Africa alone), and all ages (in contrast to children younger than five only).

Vision
Safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication.

Strategic goals
By 2030, license vaccines targeting Plasmodium falciparum and Plasmodium vivax that encompass the following two objectives, for use by the international public health community:
:: Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria-endemic areas.
:: Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.

Note for media:
http://www.who.int/mediacentre/news/notes/2013/malaria-vaccines-20131114/en/index.html

Biometric vaccine records now in place for thousands in Kenya, Uganda, Benin and Zambia

   Lumidigm announced that as a result of its multispectral imaging fingerprint sensors “biometric vaccine records are now in place for tens of thousands of adults and children in Kenya, Uganda, Benin and Zambia” and that the solution – supplied in partnership with Fulcrum Biometrics – is “helping to stop vaccine waste for the millions of Africans not yet vaccinated.” The company noted that the delivery model in many parts of Africa “depends on a multitude of healthcare workers who serve very large and remote areas. When there are no vaccination records to consult, many patients are re-immunized unnecessarily, others are simply missed and a finite supply of vaccine is wasted. Unfortunately, without a proper and reliable means of identification, vaccine wastage rates are higher than 50 percent in some of the most challenging geographies.” VaxTrac is solving this problem with a biometric vaccination registry that is operated and managed in the field with low-cost mobile devices. Adult and child patients “are identified in the registry with fingerprint sensors from Lumidigm. Returning patients can pull up their vaccination records with the touch of a finger allowing the healthcare worker to deliver appropriate care.”

More at: http://www.businesswire.com/news/home/20131112006254/en/Lumidigm-Fingerprint-Sensors-Track-Vaccination-Histories-Children

IFFIm: Rating downgrade action by Standard and Poor’s follows France downgrade

IFFIm: Rating downgrade action by Standard and Poor’s follows France downgrade
Standard & Poor’s has downgraded the long-term credit rating of the International Finance Facility for Immunisation (IFFIm) from AA+ to AA with a stable outlook. The short-term rating on IFFIm remains unchanged at A-1+.

S&P explained the decision as being linked to its rating action on France today. France is the second largest financial contributor to IFFIm.

“IFFIm, donor countries and the World Bank continuously reiterate their full confidence in IFFIm’s mission and overall financial position, as well as the commitment of donor countries to fulfill their pledging obligations,” said René Karsenti, Chair of the IFFIm Board. “The downgrade is not expected to impact the amount of funds available to IFFIm and GAVI.”

IFFIm is currently rated AA+ by Fitch with stable outlook, Aa1 by Moody’s with a negative outlook and AA by S&P with a stable outlook.
http://www.iffim.org/library/news/press-releases/2013/iffim-rating-action-by-standard-and-poor-s-follows-france-downgrade/

WHO: Summary of the SAGE November 2013 meeting

WHO: Summary of the SAGE November 2013 meeting
C. Scudamore
Full text

11 November 2013 – While acknowledging the progress made in endemic countries to date – including the absence of type 3 wild poliovirus cases, the 40% decline in polio cases in endemic countries, and the absence of endemic virus in Afghanistan – the Strategic Advisory Group of Experts (SAGE) on immunization echoed the alarm of the Independent Monitoring Board that the insecurity and lack of access for vaccinators in large areas of northwest Pakistan and northeastern states in Nigeria now constituted the greatest risk to completing polio eradication.

This risk was compounded by the increasing international spread of the virus into the Horn of Africa and the Middle East in 2013, particularly into highly vulnerable areas such as south/central Somalia and Syria where vaccinator access and security were also severely compromised.

SAGE provided several recommendations to address the wild polio virus risks and in relation to IPV introduction globally in the context of the polio endgame, including:
:: countries introducing 1 dose of inactivated polio vaccine (IPV) into the routine immunization schedule should administer the dose at or after 14 weeks of age, in addition to the 3-4 doses of oral polio vaccine (OPV) in the primary vaccination series;
:: countries have flexibility to consider alternative schedules (e.g. earlier IPV administration) based on local conditions (e.g. documented risk of vaccine-associated paralytic poliomyelitis or VAPP prior to 4 months of age); and
:: to help accelerate eradication and reduce vulnerability, all polio endemic countries should establish a plan for IPV introduction by mid-2014 and other high-risk countries by end-2014.

SAGE endorsed the proposed strategy on IPV supply, financing and introduction including the tiering of countries based on the risk of circulating vaccine-derived poliovirus (cVDPV) emergence and spread.

SAGE discussed the first annual report on the implementation of the Decade of Vaccine (DoV) Global Vaccine Action Plan (GVAP). SAGE endorsed the following recommendations as the major areas of necessary focus: 1. Improving data quality, 2. Increasing immunization coverage, 3. Accelerating progress towards measles and rubella/CRS elimination, and 4. Enhancing country ownership of national programmes. This should allow the WG to prioritize the specific issues to focus on during the next few years.

SAGE expressed its grave concern around the current situation in Syria and its neighboring countries as reported by the Eastern Mediterranean region (EMR). Effectiveness of immunization campaigns to stop the spread of polio and measles were not able to achieve the envisaged level of immunization coverage. SAGE reemphasized the need for political intervention as well as financial and technical support to countries affected by the current crisis to sustain adequate health services. Coordinated involvement of partners was crucial to stabilize the situation; SAGE encouraged donors to provide additional funding to support and strengthen routine immunization and enable conduction of urgently required interventions such as high quality supplementary immunization activities.

SAGE also expressed deep concern about the mounting challenges being faced by in-country supply chain systems that are stretched to effectively manage existing vaccines and handle the surge of new ones to be introduced and wants to draw the attention of all partners on this issue and encourage greater investments and attention to strengthening immunization supply chain systems in-country.

SAGE concluded that the recommending bodies, including WHO, need to clearly quantify and communicate the favorable risk benefit ratio of maternal immunization, and to engage in a dialogue with regulators and manufacturers to review current regulatory practices against the evidence on risks and benefits and biological plausibility on product safety. SAGE requested the secretariat to develop a process and a plan to move this agenda forward creating alignment between data safety evidence, public health needs and regulatory processes.

SAGE recommended that no physical stockpile on H5N1 vaccine should be created in view of the Pandemic Influenza Preparedness Framework provisions, on condition that equity is considered and established when vaccine is distributed to low and middle income countries.

The meeting report will be published in the WHO Weekly Epidemiological Record on 3 January 2014.
View the meeting documents, including presentations and background readings
http://www.who.int/immunization/sage/report_summary_november_2013/en/index.html

BMJ – Head to Head: Should influenza vaccination be mandatory for healthcare workers?

British Medical Journal
16 November 2013 (Vol 347, Issue 7933)
http://www.bmj.com/content/347/7933

Head to Head
Should influenza vaccination be mandatory for healthcare workers?
BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6705 (Published 12 November 2013)
Amy Behrman, medical director, occupational medicine1,
Will Offley, casualty nurse 2
   Amy Behrman believes that mandatory vaccination is needed to protect vulnerable patients, but Will Offley argues that evidence on effectiveness is not sufficient to over-ride healthcare workers’ right to choose

Yes—Amy Behrman
Advocacy for influenza vaccination begins with recognising the impact of the disease. Globally, seasonal influenza causes an estimated 300 000-500 000 deaths and 3-5 million cases of severe disease every year.1 Methods that distinguish between influenza and other viruses causing influenza-like illnesses estimate that influenza infections and complications cause an average 226 000 hospital admissions annually in the United States, including 3000-49 000 deaths, depending on seasonal severity.2 Influenza vaccines are estimated to prevent thousands of admissions and millions of illnesses annually with current usage.3 4 5

Complications and deaths from influenza are highest in elderly people, infants, and patients with compromised cardiopulmonary or immune systems.1 2 6 These vulnerable populations are most likely to enter healthcare settings and least likely to mount effective immune responses to vaccination.2 6 Influenza vaccines have excellent safety records6 and are most effective (59% reduction in laboratory proved influenza6 and 47-73% reduction in influenza-like illness2) in healthy non-elderly adults, precisely the demographic of most healthcare workers.

Nosocomial transmission is well documented.7 Influenza infection control should include, in addition to vaccination, hand hygiene, isolation of infected patients, targeted masking, and leave of absence for healthcare workers with influenza-like illness.8 Vaccination is a keystone intervention, differing from others by reducing risk in all encounters without repeated effort or time from busy healthcare workers.

Annual vaccination is therefore widely recommended to reduce the risk of healthcare acquired influenza.2 8 9 10 11 12 13 Advocates and opponents of mandatory vaccination share goals of enhancing patient and staff safety. Disagreements centre on evidence of efficacy, ethical concerns, and how best to achieve meaningful levels of immunisation. My institution’s evolution to a mandatory policy epitomises the issues.

Mandatory vaccination in practice
The University of Pennsylvania Health System has 18 000 staff. Immunisations are free for all vaccine preventable occupational infections. Influenza vaccine has been offered annually since 2003 but was initially voluntary. Uptake by healthcare workers averaged <40%, and many staff avoided immunisation even during years with clear evidence of hospital transmission. Despite prioritisation of influenza vaccination through enhanced availability on all units and shifts and at “flu fairs” with educational materials, over two years, vaccination rose to an unimpressive 45%.

We implemented declination forms in 2006-07 to survey the concerns of unvaccinated staff. As in other institutions, many declined because they underestimated influenza morbidity, feared vaccination would cause illness, or believed “clean living” would prevent transmission. Vaccination rates crept to 50%.

In 2008, we further increased outreach, including a music video addressing the concerns highlighted in the survey (www.youtube.com/watch?v=ruGgZbAVnko). Talented staff participated enthusiastically; the video played continuously; compliance inched to 54%.

By 2009, we perceived limits to non-mandatory immunisation despite maximal efforts. In an anonymous survey, 85% of medical staff supported mandatory immunisation, with 90% agreeing that healthcare workers have an ethical obligation to be vaccinated annually.14   Evidence for patient benefit from immunisation of staff working in long term care, although imperfect, supported our aim to improve compliance among our healthcare workers.15 16 17 18 19 Other mandatory programmes had achieved strikingly increased compliance without safety problems.20 21

In 2009, our health system approved a mandatory policy for all staff. Implementation was complicated by the H1N1 epidemic, with dual vaccine shortages necessitating a tiered approach to prioritise medically compromised staff and those caring for the most vulnerable patients.  Despite this, 99% of staff were vaccinated for seasonal influenza.

Subsequently, medical and religious exemptions have remained stable at <2%, while the mandatory policy is largely accepted as integral to patient and staff safety. Exempted staff are transferred from vulnerable patient units while influenza circulates. Non-compliant staff face escalating penalties (beginning with written warnings), which have been successful without having to terminate employment. Nosocomial influenza has decreased from significant to negligible since 2010, albeit with complementary policies for hand hygiene, isolation of those with influenza-like illnesses, testing healthcare workers with influenza symptoms, and leave of absence for staff with transmissible illnesses. A preliminary safety review of 40 560 staff immunisations over three years found 29 associated clinical complaints, of which eight (0.02%) were systemic symptoms possibly related to vaccination. The remaining 21 (0.05%) were arm pain likely related to injection. All symptoms resolved fully.

Mandatory vaccination is effective and ethical
Recent studies robustly support the effectiveness of mandatory policies in improving vaccination rates.7 20 21 22 Proving that vaccination of healthcare workers decreases the risk of transmission is more difficult for reasons including suboptimal immunisation rates, variable viral severity and vaccine effectiveness, visitor exposures, evolving laboratory diagnostics, and the confounding effects of other infection control interventions. Nevertheless, existing research from long term care facilities supports increasing healthcare workers vaccination to improve patient outcomes.8 15 16 17 18 19 Although acute and ambulatory care patients are likely to be discharged before nosocomial influenza can be recognised, the principles of transmission and immunity are the same,8 23 24 and these patients also deserve vaccinated healthcare workers.    More definitive studies and better vaccines are wanted,1 6 7 but existing vaccines are safe and effective for healthy adults.2 4 6 Mandatory policies make them more effective.

Finally, healthcare workers have an ethical imperative to prevent harm to patients.25 Healthcare workers can infect patients,7 8 and influenza vaccination reduces adult infections,1 3 6 24 therefore vaccination of healthcare workers should reduce risk while setting an example for patients and communities to get recommended immunisations. Maximising compliance should optimise outcomes.8 19 23 Ideally, healthcare workers will take individual responsibility for being fully immunised. When this does not occur, healthcare institutions have an ethical obligation to intervene, just as they do to optimise handwashing and minimise surgical site errors. Mandatory vaccination policies accomplish this.

Healthcare institutions should maximise the use and benefit of a vaccine that is moderately effective, extremely safe, and logically likely to reduce the risk of healthcare acquired influenza for vulnerable patients as well as decrease illness among healthcare workers. First do no harm.

No—Will Offley
The debate around compulsory influenza vaccination for healthcare workers revolves around one central question: does current scientific evidence justify over-ruling the right to informed consent to an invasive and imperfect medical procedure, with documented risks of adverse effects.

Many in this debate answer in the affirmative. For them, patient safety outweighs the right of healthcare workers to refuse influenza vaccines. They argue that compulsory vaccination is consistent with the ethic to “do no harm” and protects vulnerable people from contracting influenza from their caregivers. The only problem is that there is no persuasive scientific evidence to support this view.

Benefits are unproved
Vaccinating healthcare workers against influenza has not been shown to reduce the transmission of influenza to patients. A recent Cochrane review of five studies (four cluster randomised studies and one cohort trial of nearly 20 000 healthcare workers) concluded that “there is no evidence that only vaccinating healthcare workers prevents laboratory-proven influenza or its complications (lower respiratory tract infection, hospitalization or death due to lower respiratory tract infection) in individuals in [long term care] and thus no evidence to mandate compulsory vaccination of healthcare workers.”26

Several of Canada’s leading influenza researchers have also noted the lack of evidence that vaccination of healthcare workers reduces the incidence of influenza in patients.27 Even groups that support mandatory immunisation such as the Centers for Disease Control and Prevention (CDC)28 and Association of Medical Microbiology and Infectious Disease Canada29 have had to acknowledge the lack of data to support this assertion.

Mistaken beliefs
The argument for mandatory vaccination rests on several major fallacies that combine to inflate the perceived effect and virulence of influenza and exaggerate the effectiveness of influenza vaccines.

Firstly, the burden of disease represented by influenza is often expressed by referring to surveillance statistics. In the United States, the CDC attributes 3000 to 49 000 deaths annually to influenza.30 However, its final data for 2010 show that of the 50 097 deaths recorded for influenza and pneumonia combined, only 500 were from influenza.31 In addition, the threat from seasonal influenza is dropping, not increasing. Mortality in the US has dropped from 30-40/100 000 cases in the mid-1930s to less than 5/100 000 from the 1950s onwards, and before the advent of mass public immunisation campaigns.32

Another problem is that influenza vaccines only protect against influenza. However, 85% of influenza-like illness is not caused by influenza but by any of about 200 viral and bacterial pathogens, none of which is prevented by seasonal influenza vaccines.32

Furthermore, the ability of influenza vaccines to prevent true influenza varies considerably from year to year. It has varied from a reported high of 93%33 to a low of 4.6% in a nine year study from California.34 In 2012, vaccine effectiveness against the dominant A(H3N2) influenza was 47% in the US35 and 45% in Canada.36

Recent European studies conducted during the 2011-12 season and involving more than 9000 participants have reported that the effectiveness of influenza vaccine dropped by more than 50% within four months of being vaccinated.37 Thus vaccination imparts only partial immunity to begin with, and even that does not seem to last for the full length of an influenza season.

It is therefore unsurprising that the American College of Occupational and Environmental Medicine has adopted a position against compulsory influenza vaccination, stating that current evidence regarding its ability to protect patients “is inadequate to override the worker’s autonomy to refuse vaccination.”13 The US Occupational Safety and Health Administration, which is responsible for workplace health and safety, has stated that “there is insufficient evidence for the federal government to promote mandatory influenza vaccination programmes that may result in employment termination.”38

Risks of vaccination
Influenza vaccines are relatively safe, not absolutely safe. Adverse effects, while uncommon, are nonetheless real, particularly (but not exclusively) for children and adolescents. Studies indicate that individuals receiving trivalent inactivated vaccine have a one in a million chance of contracting Guillain-Barré syndrome39 and a 13% higher incidence of oculorespiratory syndrome.40 Happily, most of these reactions have been limited to certain manufacturers and formulations, although not all were discovered before the vaccine was administered.41 A Canadian study also found a 1.4 to 2.5 higher rate of pandemic H1N1 influenza among people who had received the 2008 seasonal influenza vaccine, which did not contain this strain.42

Ethical rights of staff
Compulsory vaccination against seasonal influenza is based on an exaggerated threat and an exaggerated cure. Despite a lack of reliable, disinterested scientific evidence to show that healthcare workers are an important source of transmission to our patients, mandatory vaccination is promoted as a panacea without due regard to risks. Compulsion strips healthcare providers of a basic right guaranteed to every other patient—the right to informed consent.

Healthcare workers can and must make a real contribution to protecting patients from influenza—by isolating patients with symptoms of respiratory infection, improving infection control, covering our coughs, washing our hands, and, above all, staying home when we are sick. But until there is more persuasive evidence, it is neither a breach of ethics nor a disservice to patients to insist that influenza vaccination remains a personal decision based on informed consent.

http://www.bmj.com/content/347/bmj.f6705

Preventive misconception and adolescents’ knowledge about HIV vaccine trials

Journal of Medical Ethics
December 2013, Volume 39, Issue 1
http://jme.bmj.com/content/current

Research ethics
Paper
Preventive misconception and adolescents’ knowledge about HIV vaccine trials
Mary A Ott1, Andreia B Alexander1, Michelle Lally2, John B Steever3, Gregory D Zimet1, the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions

Author Affiliations
1Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
2Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA
3Department of Pediatrics, Mount Sinai School of Medicine, New York, New York, USA
Correspondence to Dr Mary A Ott, Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, 410 West 10th Street, HS 1001, Indianapolis, IN 46202, USA;
http://jme.bmj.com/content/39/12/765.abstract

Abstract 
Objective  Adolescents have had very limited access to research on biomedical prevention interventions despite high rates of HIV acquisition. One concern is that adolescents are a vulnerable population, and trials carry a possibility of harm, requiring investigators to take additional precautions. Of particular concern is preventive misconception, or the overestimation of personal protection that is afforded by enrolment in a prevention intervention trial.

Methods  As part of a larger study of preventive misconception in adolescent HIV vaccine trials, we interviewed 33 male and female 16–19-year-olds who have sex with men. Participants underwent a simulated HIV vaccine trial consent process, and then completed a semistructured interview about their understanding and opinions related to enrolment in a HIV vaccine trial. A grounded theory analysis looked for shared concepts, and focused on the content and process of adolescent participants’ understanding of HIV vaccination and the components of preventive misconception, including experiment, placebo and randomisation.

Results  Across interviews, adolescents demonstrated active processing of information, in which they questioned the interviewer, verbally worked out their answers based upon information provided, and corrected themselves. We observed a wide variety of understanding of research concepts. While most understood experiment and placebo, fewer understood randomisation. All understood the need for safer sex even if they did not understand the more basic concepts.

Conclusions  Education about basic concepts related to clinical trials, time to absorb materials and assessment of understanding may be necessary in future biomedical prevention trials.

Lancet – Comment: Polio lessons 2013: Israel, the West Bank, and Gaza

The Lancet  
Nov 16, 2013   Volume 382 Number 9905  p1609 – 1678 e23 – 24
http://www.thelancet.com/journals/lancet/issue/current

Comment
Polio lessons 2013: Israel, the West Bank, and Gaza
Theodore H Tulchinsky, Asad Ramlawi, Ziad Abdeen, Itamar Grotto, Antoine Flahault
Preview |
In 2013, Israel’s Ministry of Health reported that wild poliovirus (ie, non Sabin) type 1 (WPV1) had been detected in many environmental sewage samples from southern and central Israel.1 WHO also reported that WPV1 had been isolated in Israeli sewage samples and in stool samples; by contrast, there were only three positive sewage samples in the West Bank and one in the Gaza Strip, with no positive stool samples from ten samples from patients with suspected acute flaccid paralysis.2 The virus has been identified as the same virus present in Egypt; both viruses are related to the WPV1 still endemic in Pakistan.

Vaccination for the control of childhood bacterial pneumonia – Haemophilus influenzae type b and pneumococcal vaccines

Pneumonia
Vol 2 (2013)
https://pneumonia.org.au/index.php/pneumonia/issue/current

Vaccination for the control of childhood bacterial pneumonia – Haemophilus influenzae type b and pneumococcal vaccines
Diana C Otczyk, Allan W Cripps
https://pneumonia.org.au/index.php/pneumonia/article/view/229
Abstract
Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines are currently available against the leading bacterial causes of pneumonia.  The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children.  However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement.  The current vaccines provide serotype-specific, antibody–mediated protection against only a few of the 90+ capsule serotypes.  Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries.  The next generation of pneumococcal vaccines have advanced to clinical trials.

Delivering vaccines for the prevention of pneumonia – programmatic and financial issues

Pneumonia
Vol 2 (2013)
https://pneumonia.org.au/index.php/pneumonia/issue/current

Delivering vaccines for the prevention of pneumonia – programmatic and financial issues
Diana C Otczyk, Allan W Cripps
https://pneumonia.org.au/index.php/pneumonia/article/view/244
Abstract
Pneumonia is the leading cause of morbidity and mortality in children younger than 5 years. Vaccines are available against the main bacterial pathogens Haemophilus influenzae type b and Streptococcus pneumoniae.  There are also vaccines against measles and pertussis; diseases that can predispose a child to pneumonia.   Partners such as GAVI, the Hib Initiative, the Accelerated Development and Introduction Plan for pneumococcal vaccines and the Measles Initiative have accelerated the introduction of vaccines into developing countries.  Whilst significant improvements in vaccine coverage have occurred globally over the past decade, there still remains an urgent need to scale-up key pneumonia protection and treatment interventions as identified in the Global Action Plan for the Prevention and Control of Pneumonia (GAPP).  There is promise that global immunisation will continue to improve child survival.    However, there are several challenges to vaccine implementation that must first be addressed, including: a lack of access to under-served and marginalised populations; inadequate planning and management; a lack of political commitment; weak monitoring and surveillance programmes and assured sustainable finance and supply of quality vaccines.  There is an urgent need to increase global awareness of the devastation that pneumonia brings to the world’s poorest communities.

Vaccinomics, the new road to tick vaccine

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 50, Pages 5923-6040 (5 December 2013)

Vaccinomics, the new road to tick vaccines
Original Research Article
Pages 5923-5929
José de la Fuente, Octavio Merino

Abstract
Ticks are a threat to human and animal health worldwide. Ticks are considered to be second worldwide to mosquitoes as vectors of human diseases, the most important vectors of diseases that affect cattle industry worldwide and important vectors of diseases affecting pets. Tick vaccines are a cost-effective and environmentally friendly alternative to protect against tick-borne diseases through the control of vector infestations and reducing pathogen infection and transmission. These premises stress the need for developing improved tick vaccines in a more efficient way. In this context, development of improved vaccines for tick-borne diseases will be greatly enhanced by vaccinomics approaches starting from the study of tick–host–pathogen molecular interactions and ending in the characterization and validation of vaccine formulations. The discovery of new candidate vaccine antigens for the control of tick infestations and pathogen infection and transmission requires the development of effective screening platforms and algorithms that allow the analysis and validation of data produced by systems biology approaches to tick research. Tick vaccines that affect both tick infestations and pathogen transmission could be used to vaccinate human and animal populations at risk and reservoir species to reduce host exposure to ticks while reducing the number of infected ticks and their vectorial capacity for pathogens that affect human and animal health worldwide.

IInfectious disease research investments: Systematic analysis of immunology and vaccine research funding in the

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 50, Pages 5923-6040 (5 December 2013)

Infectious disease research investments: Systematic analysis of immunology and vaccine research funding in the UK
Original Research Article
Pages 5930-5933
Joseph R. Fitchett, Michael G. Head, Rifat Atu

Abstract
Financing for global health is a critical element of research and development. Innovations in new vaccines are critically dependent on research funding given the large sums required, however estimates of global research investments are lacking. We evaluate infectious disease research investments, focusing on immunology and vaccine research by UK research funding organisations. In 1997–2010, £2.6 billion were spent by public and philanthropic organisations, with £590 million allocated to immunology and vaccine research. Preclinical studies received the largest funding amount £505 million accounting for 85.6% of total investment. In terms of specific infection, “the big three” infections dominated funding: HIV received £127 million (21.5% of total), malaria received £59 million (10.0% of total) and tuberculosis received £36 million (6.0% of total). We excluded industry funding from our analysis, as open-access data were unavailable. A global investment surveillance system is needed to map and monitor funding and guide allocation of scarce resources.

Evaluating the safety of influenza vaccine using a claims-based health system

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 50, Pages 5923-6040 (5 December 2013)

Evaluating the safety of influenza vaccine using a claims-based health system
Original Research Article
Pages 5975-5982
Natalie L. McCarthy, Julianne Gee, Nancy D. Lin, Veena Thyagarajan, Yi Pan, Sue Su, Bruce Turnbull, K. Arnold Chan, Eric Weintraub

Abstract
Introduction
As part of the Centers for Disease Control and Prevention’s monitoring and evaluation activities for influenza vaccines, we examined relationships between influenza vaccination and selected outcomes in the 2009–2010 and 2010–2011 influenza seasons in a claims-based data environment.

Methods
We included patients with claims for trivalent influenza vaccine (TIV) and/or 2009 pandemic influenza A H1N1 vaccine (H1N1) during the 2009–2010 and 2010–2011 influenza seasons. Patients were followed for several pre-specified outcomes identified in claims. Seizures and Guillain–Barré Syndrome were selected a priori for medical record confirmation. We estimated incidence rate ratios (IRR) using a self-controlled risk interval (SCRI) or a historical comparison design. Outcomes with elevated IRRs, not selected a priori for medical record review, were further investigated with review of claims histories surrounding the outcome date to determine whether the potential event could be ruled-out or attributed to other causes based on the pattern of medical care.

Results
In the 2009–2010 season, no significant increased risks for outcomes following H1N1 vaccination were observed. Following TIV administration, the IRR for peripheral nervous system disorders and neuropathy was slightly elevated (1.07, 95% CI: 1.01–1.13). The IRR for anaphylaxis following TIV was 28.55 (95% CI: 3.57–228.44). After further investigation of claims histories, the majority of potential anaphylaxis cases had additional claims around the time of the event indicating alternate explanatory factors or diagnoses. In the 2010–2011 season following TIV administration, a non-significant elevated IRR for anaphylaxis was observed with no other significant outcome findings.

Conclusion
After claims history review, we ultimately found no increased outcome risk following administration of 998,881 TIV and 538,257 H1N1 vaccine doses in the 2009–2010 season, and 1,158,932 TIV doses in the 2010–2011 season

A cluster randomised controlled trial of a web based decision aid to support parents’ decisions about their child’s Measles Mumps and Rubella (MMR) vaccination

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 50, Pages 5923-6040 (5 December 2013)

A cluster randomised controlled trial of a web based decision aid to support parents’ decisions about their child’s Measles Mumps and Rubella (MMR) vaccination
Original Research Article
Pages 6003-6010
S. Shourie, C. Jackson, F.M. Cheater, H.L. Bekker, R. Edlin, S. Tubeuf, W. Harrison, E. McAleese, M. Schweiger, B. Bleasby, L. Hammond

Abstract
Objective
To evaluate the effectiveness of a web based decision aid versus a leaflet versus, usual practice in reducing parents’ decisional conflict for the first dose MMR vaccination decision. The, impact on MMR vaccine uptake was also explored.

Design
Three-arm cluster randomised controlled trial. Setting: Fifty GP practices in the north of, England. Participants: 220 first time parents making a first dose MMR decision. Interventions: Web, based MMR decision aid plus usual practice, MMR leaflet plus usual practice versus usual practice only, (control). Main outcome measures: Decisional conflict was the primary outcome and used as the, measure of parents’ levels of informed decision-making. MMR uptake was a secondary outcome.

Results
Decisional conflict decreased post-intervention for both intervention arms to a level where, parents could make an informed MMR decision (decision aid: effect estimate = 1.09, 95% CI −1.36 to −0.82; information leaflet: effect estimate = −0.67, 95% CI −0.88 to −0.46). Trial arm was significantly, associated (p < 0.001) with decisional conflict at post-intervention. Vaccination uptake was 100%, 91%, and 99% in the decision aid, leaflet and control arms, respectively (χ2 (1, N = 203) = 8.69; p = 0.017). Post-hoc tests revealed a statistically significant difference in uptake between the information leaflet, and the usual practice arms (p = 0.04), and a near statistically significant difference between the, decision aid and leaflet arms (p = 0.05).

Conclusions
Parents’ decisional conflict was reduced in both, the decision aid and leaflet arms. The decision aid also prompted parents to act upon that decision and, vaccinate their child. Achieving both outcomes is fundamental to the integration of immunisation, decision aids within routine practice. Trial registration: ISRCTN72521372.

Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 50, Pages 5923-6040 (5 December 2013)

Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza
Original Research Article
Pages 6030-6033
Walter E.P. Beyer, Janet McElhaney, Derek J. Smith, Arnold S. Monto, Jonathan S. Nguyen-Van-Tam, Albert D.M.E. Osterhaus

Abstract
The 2010 Cochrane review on efficacy, effectiveness and safety of influenza vaccination in the elderly by Jefferson et al. covering dozens of clinical studies over a period of four decades, confirmed vaccine safety, but found no convincing evidence for vaccine effectiveness (VE) against disease thus challenging the ongoing efforts to vaccinate the elderly.

However, the Cochrane review analyzed and presented the data in a way that may itself have hampered the desired separation of real vaccine benefits from inevitable ‘background noise’. The data are arranged in more than one hundred stand-alone meta-analyses, according to various vaccine types, study designs, populations, and outcome case definitions, and then further subdivided according to virus circulation and antigenic match. In this way, general vaccine effects could not be separated from an abundance of environmental and operational, non vaccine-related variation. Furthermore, expected impacts of changing virus circulation and antigenic drift on VE could not be demonstrated.

We re-arranged the very same data according to a biological and conceptual framework based on the basic sequence of events throughout the ‘patient journey’ (exposure, infection, clinical outcome, observation) and using broad outcome definitions and simple frequency distributions of VE values. This approach produced meaningful predictions for VE against influenza-related fatal and non-fatal complications (average ∼30% with large dispersion), typical influenza-like illness (∼40%), disease with confirmed virus infection (∼50%), and biological vaccine efficacy against infection (∼60%), under conditions of virus circulation. We could also demonstrate a VE average around zero in the absence of virus circulation, and decreasing VE values with decreasing virus circulation and increasing antigenic drift.

We regard these findings as substantial evidence for the ability of influenza vaccine to reduce the risk of influenza infection and influenza-related disease and death in the elderly.

HPV vaccination in Hong Kong: Uptake and reasons for non-vaccination amongst Chinese adolescent girls

Vaccine
Volume 31, Issue 49, Pages 5785-5922 (2 December 2013)

HPV vaccination in Hong Kong: Uptake and reasons for non-vaccination amongst Chinese adolescent girls
Pages 5785-5788
Sophia Ling Li, Yu Lung Lau, Tai Hing Lam, Paul Siu Fai Yip, Susan Yun Sun Fan, Patrick Ip

Abstract
Objectives
The study aims to determine HPV vaccine uptake (≥1 dose) amongst adolescent girls in Hong Kong and to explore the reasons for non-acceptance of the vaccine.

Study design
A total of 1832 secondary school girls (15.5 ± 2.0 years) were randomly surveyed. Their HPV vaccine uptake was estimated, and their reasons for non-vaccination summarised.

Results
A total of 131 (7.2%, 95% CI: 6.0–8.4%) adolescent girls had received the HPV vaccine (≥1 dose). Vaccine uptake was positively associated with a higher maternal education level and locally born status. Amongst the non-vaccinated girls, 20.6% had never heard of or knew little about the vaccine, 20.2% ‘did not know where to receive’, and 17.8% were concerned about the cost.

Conclusions
The HPV vaccine uptake amongst adolescent girls in Hong Kong is very low. A school-based education and service programme is needed to improve uptake and prevent disparities in the Chinese population.

Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink

Vaccine
Volume 31, Issue 49, Pages 5785-5922 (2 December 2013)

Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink
Original Research Article
Pages 5822-5826
Natalie L. McCarthy, Stephanie Irving, James G. Donahue, Eric Weintraub, Julianne Gee, Edward Belongia, James Baggs

Abstract
Introduction
The Vaccine Safety Datalink (VSD) is a collaborative project whose infrastructure provides comprehensive medical and immunization histories for more than 9 million adults and children annually, a predominantly insured population. This study provides the coverage rates of recommended vaccines among children 19–35 months in the VSD from 2005 through 2010. We examine the consistency in vaccine coverage levels, detect possible trends, and evaluate any effect of vaccine shortages on coverage in the VSD.

Methods
We included data from all 10 VSD sites, and examined each year independently. Coverage rates were defined as the percentage of children in the VSD aged 19, 24, or 35 months in a given study year who had received the specified Advisory Committee on Immunization Practices (ACIP) recommended vaccine(s).

Results
We assessed coverage on 658,154 children. The overall coverage rate for children receiving all of the specified ACIP recommended vaccines was 73%, 80%, and 78% at ages 19, 24, and 35 months respectively. The range of coverage across all ages and years was 95–97% for polio vaccine, 91–97%, for MMR vaccine, 94–97% for HepB vaccine, 81–95% for DTaP vaccine, 90–95% for varicella vaccine, 66–91% for PCV, and 93–98% for Hib vaccine. Coverage rates of 4 or more doses of PCV were relatively low in 2005 possibly due to a vaccine shortage, and increased sharply in 2007. Hib vaccine coverage was relatively stable among all ages until 2009 when rates declined among children aged 19 and 24 months also during a vaccine shortage.

Conclusions
Vaccine coverage in the VSD is high, but there is a decline from 2005 to 2010. The results of this study provide benchmark data for future studies, and describe how vaccine supply shortages and resulting changes in ACIP recommendations may have affected vaccine coverage rates in the VSD.

Impact of medical education on knowledge and attitudes regarding the human papilloma virus and vaccination: Comparison before and 6 years after the introduction of the vaccines

Vaccine
Volume 31, Issue 49, Pages 5785-5922 (2 December 2013)

Impact of medical education on knowledge and attitudes regarding the human papilloma virus and vaccination: Comparison before and 6 years after the introduction of the vaccines
Original Research Article
Pages 5843-5847
K.W.M. D’Hauwers, P.F.E. Gadet, A.R.T. Donders, W.A.A. Tjalma

Abstract
Aim
The lifetime risk for acquiring a human papilloma virus (HPV) infection is 80% for sexually active people. High-risk HPVs are causally related to almost every case of cervical cancer, and to a subgroup of vaginal, vulvar, anal, penile and oral/oropharyngeal cancer. Low-risk HPVs are related to cutaneous, anogenital, and oral warts.
Two prophylactic vaccines were launched in 2007: they were included in the national vaccination program in Belgium (2009) and in the Netherlands (2010). The objectives of the present study were to determine and compare knowledge and attitudes regarding HPV and vaccination among a study population in 2006 and in 2012.

Materials and methods
Shortly before the introduction, and three years after the inclusion, 715 (2006) and 678 participants (2012) were questioned. Participants were categorised as into non-medics, medics, or paramedics.

Results
In general, knowledge about HPV has increased over time (p < 0.01).
Well-known facts are the relationship of HPV with cervical cancer (>94% in 2006; >96% in 2012), and that an HPV infection might be asymptomatic (>95% in 2006; >99% in 2012).
In 2012, versus in 2006, paramedics and non-medics (both p < 0.01), were more likely to vaccinate all female teenagers. Medics were less likely to support this (p = 0.001). More respondents agreed to vaccinate their daughters (p < 0.01), as well as their sons (p < 0.01).
In 2012, when compared with 2006, less non-medics and medics (both p < 0.01) and more paramedics (p = 0.001) would accept a free catch-up vaccination. Arguments against catch-up vaccination reflected the belief not being at risk and doubts about the vaccines’ safety.

Conclusion
The facts that vaccination programs are regarded as being important, and that knowledge on HPV increased, do not automatically result in an increase in participation in HPV vaccination programs. To increase participation, information must be provided with arguments that cannot be misinterpreted.

Can vaccine legacy explain the British pertussis resurgence?

Vaccine
Volume 31, Issue 49, Pages 5785-5922 (2 December 2013)

Can vaccine legacy explain the British pertussis resurgence?
Original Research Article
Pages 5903-5908
Maria A. Riolo, Aaron A. King, Pejman Rohani

Abstract
Pertussis incidence has been rising in some countries, including the UK, despite sustained high vaccine coverage. We questioned whether it is possible to explain the resurgence without recourse to complex hypotheses about pathogen evolution, subclinical infections, or trends in surveillance efficiency. In particular, we investigated the possibility that the resurgence is a consequence of the legacy of incomplete pediatric immunization, in the context of cohort structure and age-dependent transmission. We constructed a model of pertussis transmission in England and Wales based on data on age-specific contact rates and historical vaccine coverage estimates. We evaluated the agreement between model-predicted and observed patterns of age-specific pertussis incidence under a variety of assumptions regarding the duration of immunity. Under the assumption that infection-derived immunity is complete and lifelong, and regardless of the duration of vaccine-induced immunity, the model consistently predicts a resurgence of pertussis incidence comparable to that which has been observed. Interestingly, no resurgence is predicted when infection- and vaccine-derived immunities wane at the same rate. These results were qualitatively insensitive to rates of primary vaccine failure. We conclude that the alarming resurgence of pertussis among adults and adolescents in Britain and elsewhere may simply be a legacy of historically inadequate coverage employing imperfect vaccines. Indeed, we argue that the absence of resurgence at this late date would be more surprising. Our analysis shows that careful accounting for age dependence in contact rates and susceptibility is prerequisite to the identification of which features of pertussis epidemiology want additional explanation.

Attitude on Human Papilloma Virus vaccination

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

[PDF] Attitude on Human Papilloma Virus vaccination
V Jose, MG Nayak, P Jawahar – Int. J. Curr. Microbiol. App. Sci, 2013
… Int.J.Curr.Microbiol.App.Sci (2013) 2(11): 90-95 91 and 20 million new cases of genital herpes annually worldwide. Human Papilloma Virus (HPV) vaccine has undergone successful trials and has recently been approved for use for the primary prevention of cervical cancer…

The Cancer Vaccine [HPV]

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 16 November 2013

The Cancer Vaccine
Only one in three American girls is vaccinated against HPV. That will mean thousands of gratuitous cancer deaths. Young people in the South are especially unlikely to get the vaccine, according to a new study. Why?
James Hamblin   Nov 13 2013, 2:35 PM ET
http://www.theatlantic.com/health/archive/2013/11/the-cancer-vaccine/281365/

William Pollack Dies at 87; His Rh Vaccine Saved Infants

New York Times
http://www.nytimes.com/
Accessed 16 November 2013

William Pollack Dies at 87; His Vaccine Saved Infants
By PAUL VITELLO
Published: November 12, 2013

Dr. Pollack was a senior scientist in the research laboratory of Ortho Pharmaceutical Company in Raritan, N.J., in the early 1960s when he began a collaboration with two Columbia University researchers, Dr. Vincent J. Freda and Dr. John G. Gorman, to conceive a novel treatment for erythroblastosis fetalis, a blood disorder commonly called Rh disease. The ailment is caused by seemingly superficial differences in the blood types of pregnant women and their fetuses.

Besides the biochemical traits that define the major blood types — A, B, AB and O — the blood of 85 percent of people carries a cluster of surface proteins known as the Rh factor, named for the rhesus monkeys in which it was first identified in 1940. Blood transfusions between people who have the Rh factor (known as Rh positive) and people who do not (Rh negative) cause severe immune reactions.

Rh disease occurs when a pregnant woman is Rh negative and her fetus is Rh positive. In the mixing of blood between the two during pregnancy, the mother’s Rh-negative blood cells produce antibodies that attack the blood cells of the fetus. Depending on the strength of the mother’s immune response, the effects on the baby can range from mild anemia to stillbirth.

Dr. Pollack and his partners devised an “ingenious” counterattack, as it was described in an introduction to their work in “Hematology: Landmark Papers of the Twentieth Century,” a collection published in 2000 by hematologist organizations.

The three men produced a vaccine that patrols the mother’s body, dispatches invading Rh-positive cells and causes no harm to the fetus. The vaccine was made from a passive Rh-negative antibody, which soon wears out. It not only solves the mother’s temporary immunity problem but also, more important, prevents her immune system from mounting a full-fledged response of its own, which would endanger the fetus she was carrying as well as any future ones.

“It was an absolutely brilliant idea,” said Dr. Richard L. Berkowitz, the obstetrics and gynecology director of resident education at NewYork-Presbyterian/Columbia hospital. “A lot of people know who Jonas Salk is, but they should know William Pollack’s name, too. This disease was a major, major problem, and it’s been virtually eradicated.”

http://www.nytimes.com/2013/11/13/us/william-pollack-dies-at-87-his-vaccine-saved-infants.html?_r=0

Vaccines and Global Health: The Week in Review 9 Nov 2013

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_9 Nov 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

Joint statement: Over 20 million children to be vaccinated in Syria and neighbouring countries

Joint statement: Over 20 million children to be vaccinated in Syria and neighbouring countries
WHO and UNICEF
8 November 2013

Excerpt
The largest-ever consolidated immunization response in the Middle East is under way to stop a polio outbreak, aiming to vaccinate over 20 million children in seven countries and territories repeatedly. Emergency immunization campaigns in and around Syria to prevent transmission of polio and other preventable diseases have vaccinated more than 650,000 children in Syria, including 116,000 in the highly-contested north-east Deir-ez-Zor province where the polio outbreak was confirmed a week ago…

The outbreak of paralytic polio among children in Syria has catalysed the current mass response. The first polio outbreak in the country since 1999, it has so far left 10 children paralyzed, and poses a risk of paralysis to hundreds of thousands of children across the region. Preliminary evidence indicates that the poliovirus is of Pakistani origin and is similar to the strain detected in Egypt, Israel, the West Bank and Palestine.

Dr. Ala Alwan, the World Health Organization Regional Director for the Eastern Mediterranean noted, “The Middle East has shown exactly the coordinated leadership needed to combat a deadline virus: a consolidated and sustained assault on a vaccine-preventable disease and an extraordinary commitment to a common purpose.”

UNICEF said it has procured 1.35 billion doses of oral polio vaccine (OPV) to date in 2013 and by the end of the year will have procured up to 1.7 billion doses to meet increased demand. Global supply of OPV was already under constraint with vaccine manufacturers producing at full capacity. The new outbreak in Syria is adding further pressure to the supply but WHO, UNICEF and manufacturers are working to secure sufficient quantities to reach all children…

http://www.unicef.org/media/media_70833.html

GPEI Update: Polio this week – As of 6 November 2013

Update: Polio this week – As of 6 November 2013
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
[Editor’s extract and bolded text]

:: Following confirmation of polio in Syria, health ministers of the Eastern Mediterranean declared the circulation of poliovirus in the Region an ‘emergency’ for all Member States at its Regional Committee meeting in Oman last week. It called on Pakistan to take necessary steps to ensure all children were accessed and vaccinated as a matter of utmost emergency to prevent further international spread and requested Syria and adjoining countries to coordinate intensified mass vaccination campaigns using the most appropriate tactics and vaccines to interrupt this new outbreak within six months. For more on the Regional Committee meeting click here.

:: The Strategic Advisory Group of Experts on immunization (SAGE) is meeting this week in Geneva, Switzerland. Among other topics, the SAGE is expected to review the latest global polio epidemiology, strategies for accelerating polio eradication and plans for introduction of inactivated poliovirus vaccine (IPV) into routine immunization.

Afghanistan
One new WPV1 case was reported in the past week (from Chapa Dara district, Kunar province). The total number of WPV cases for 2013 is now nine (all WPV1), all of which were reported from Eastern Region, close to the Pakistan border. The most recent WPV1 case had onset of paralysis on 27 September, from Kunar province.

Nigeria
Two new WPV cases were reported this week. The total number of WPV cases for 2013 is now 51 (all WPV1s). The two cases were reported from Local Government Areas (LGA) Nasarawa and Kumbotso in Kano state. The most recent WPV1 case in the country had onset of paralysis on 8 October (from Kumbotso, Kano).

GAVI Alliance welcomes introduction of pneumococcal and measles-rubella vaccines in Senegal

 The GAVI Alliance said it welcomes the introduction of pneumococcal and measles-rubella vaccines in Senegal. Dr Seth Berkley, CEO of the GAVI Alliance, said, “Senegal is investing in the health of its children by protecting them from these three potentially fatal diseases. We want to see children benefitting from the power of vaccines no matter where in the world they live.” Awa Marie Coll Seck, Senegal Health Minister, commwented, “These introductions are very important for Senegal because children are dying every day from these vaccine-preventable diseases. I am happy that we have been able to introduce these vaccines for our children with GAVI Alliance support.” Senegal plans to introduce pneumococcal vaccine into its routine child vaccination schedule immediately while the measles-rubella introduction will initially begin as a campaign before moving in to routine immunisation from the beginning of 2014.

http://www.gavialliance.org/library/news/statements/2013/gavi-alliance-welcomes-introduction-of-two-life-saving-vaccines-in-senegal/

Global Fund announces new procurement framework – US$140 million in savings

The Global Fund said it worked with partners to establish a “new framework to systematically organize the purchase of massive amounts of mosquito nets, anti-HIV drugs and other products that will improve delivery and make significant savings. In a first step, the Global Fund will sign contracts with 7 manufacturers “for the largest-ever bulk purchase of mosquito nets treated with insecticide, with immediate costs savings of  US$51.2 million, and projected overall savings of US$140 million for the Global Fund over two years.” The announcement noted that the initial contracts, for 90 million mosquito nets, will be part of an overall purchase of 190 million nets by partners in 2014. The new framework reduces base prices across the board, for all partners, and also reduces bottlenecks and shortages in countries where malaria threatens the lives of millions of children under the age of 5. The Global Fund said that the new framework emerged from a special partnership launched in May 2013 between the Global Fund, the UK’s Department for International Development, the U.S. President’s Malaria Initiative and UNICEF, who collectively represent about 87 percent of the purchases of insecticide-treated nets. Other partners also participated, including the Clinton Health Access Initiative (CHAI), Roll Back Malaria Partnership and the office of Raymond G. Chambers, the UN Secretary-General’s Special Envoy for Financing the Health MDGs and for Malaria…

http://www.theglobalfund.org/en/mediacenter/newsreleases/2013-11-05_Breakthrough_on_Procurement_to_Save_USD_140_Million/

Reports/Research/Analysis/ Conferences/Meetings/Book Watch
Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Meeting: Vaccines for Enteric Diseases (VED) Conference
Coalition against Typhoid (CaT), an initiative of the Sabin Vaccine Institute.
Scientists, researchers and biotech experts this week at the to discuss how a highly anticipated conjugate typhoid vaccine could expedite global efforts to help prevent this disease. For the first time, children as young as six months of age can be protected against typhoid with a vaccine. Both adults and children will receive high levels of long lasting protection.
http://www.sabin.org/updates/pressreleases/leaders-fight-against-typhoid-express-hope-light-new-vaccines

Forum: Human Resources for Health: foundation for Universal Health Coverage and the post-2015 development agenda.
Third Global Forum on Human Resources for Health
Recife, Brazil
10–13 November, 2013
http://www.who.int/mediacentre/events/meetings/2013/human-resources/en/index.html
Main issues for discussion
:: Learning from a decade of action on HRH with respect to efforts to achieve the health-related MDGs as well as other important national and global health goals? Are we on the right track towards universal health coverage (UHC)?
:: Matching health workforce production to population needs and expectations.
:: Social needs and the regulatory role of the State.
:: Deployment, retention and management for an effective health workforce.
:: Empowerment and incentives for health personnel as we move towards UHC.
:: Exploring a forward looking agenda to make sure the health workforce is the vanguard for UHC.

Workshop: Adult Vaccination in Middle and Low Income Countries: TB, HIV, and Malaria.
Aeras
Presentations: http://www.aeras.org/blog.

Ethical Research and Minorities: AJPH Series

American Journal of Public Health
Volume 103, Issue 12 (December 2013)
http://ajph.aphapublications.org/toc/ajph/current

Ethical Community-Engaged Research: A Literature Review.      
Lisa Mikesell, Elizabeth Bromley, and Dmitry Khodyakov.
American Journal of Public Health: December 2013, Vol. 103, No. 12, pp. e7-e14.
doi: 10.2105/AJPH.2013.301605
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2013.301605
Abstract
Health research has relied on ethical principles, such as those of the Belmont Report, to protect the rights and well-being of research participants.
Community-based participatory research (CBPR), however, must also consider the rights and well-being of communities. This requires additional ethical considerations that have been extensively discussed but not synthesized in the CBPR literature.
We conducted a comprehensive thematic literature review and summarized empirically grounded discussions of ethics in CBPR, with a focus on the value of the Belmont principles in CBPR, additional essential components of ethical CBPR, the ethical challenges CBPR practitioners face, and strategies to ensure that CBPR meets ethical standards. Our study provides a foundation for developing a working definition and a conceptual model of ethical CBPR.

Ethical Research and Minorities
Mark A. Rothstein.
American Journal of Public Health, December 2013, Vol. 103, No. 12, pp. 2118-2118.
doi: 10.2105/AJPH.2013.301390

Building Trust for Engagement of Minorities in Human Subjects Research: Is the Glass Half Full, Half Empty, or the Wrong Size?
Sandra C. Quinn, Nancy E. Kass, and Stephen B. Thomas.
American Journal of Public Health December 2013: Vol. 103, No. 12, pp. 2119-2121.
doi: 10.2105/AJPH.2013.301685

Rethinking the Vulnerability of Minority Populations in Research.
Wendy Rogers and Margaret Meek Lange.
American Journal of Public Health: December 2013, Vol. 103, No. 12, pp. 2141-2146.
doi: 10.2105/AJPH.2012.301200
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2012.301200
Abstract
The Belmont Report, produced in 1979 by a United States government commission, includes minority populations among its list of vulnerable research participants. In this article, we consider some previous attempts to understand the vulnerability of minorities in research, and then provide our own account.
First we examine the question of the representation of minorities in research. Then we argue that the best understanding of minorities, vulnerability, and research will begin with a broad understanding of the risk of individual members of minority groups to poor health outcomes.    We offer a typology of vulnerability to help with this task.
Finally, we show how researchers should be guided by this broad analysis in the design and execution of their research.

Adapting Western Research Methods to Indigenous Ways of Knowing.
Vanessa W. Simonds and Suzanne Christopher.
American Journal of Public Health: December 2013, Vol. 103, No. 12, pp. 2185-2192.
doi: 10.2105/AJPH.2012.30115
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2012.301157
Abstract
Indigenous communities have long experienced exploitation by researchers and increasingly require participatory and decolonizing research processes. We present a case study of an intervention research project to exemplify a clash between Western research methodologies and Indigenous methodologies and how we attempted reconciliation. We then provide implications for future research based on lessons learned from Native American community partners who voiced concern over methods of Western deductive qualitative analysis. Decolonizing research requires constant reflective attention and action, and there is an absence of published guidance for this process. Continued exploration is needed for implementing Indigenous methods alone or in conjunction with appropriate Western methods when conducting research in Indigenous communities. Currently, examples of Indigenous methods and theories are not widely available in academic texts or published articles, and are often not perceived as valid.

The Economic Case for Combating Malaria; Malaria Diagnostics in Clinical Trials

American Journal of Tropical Medicine and Hygiene
November 2013; 89 (5)
http://www.ajtmh.org/content/current

The Economic Case for Combating Malaria
Mark Purdy, Matthew Robinson, Kuangyi Wei, and David Rublin
Am J Trop Med Hyg 2013 89:819-823; doi:10.4269/ajtmh.12-0689
http://www.ajtmh.org/content/89/5/819.abstract

Abstract.
To date, existing studies focus largely on the economic detriments of malaria. However, if we are to create suitable incentives for larger-scale, more sustained anti-malaria efforts from a wider group of stakeholders, we need a much better understanding of the economic benefits of malaria reduction and elimination. Our report seeks to rectify this disjuncture by showing how attaining the funding needed to meet internationally agreed targets for malaria elimination would, on conservative assumptions, generate enormous economic improvements. We use a cost-benefit analysis anchored in Global Malaria Action Plan projections of malaria eradication based on fully met funding goals. By calculating the value of economic output accrued caused by work years saved and subtracting the costs of intervention, we find that malaria reduction and elimination during 2013–2035 has a 2013 net present value of US $208.6 billion.

.
Malaria Diagnostics in Clinical Trials
Sean C. Murphy*, Joseph P. Shott, Sunil Parikh, Paige Etter, William R. Prescott and V. Ann Stewart

Abstract.
Malaria diagnostics are widely used in epidemiologic studies to investigate natural history of disease and in drug and vaccine clinical trials to exclude participants or evaluate efficacy. The Malaria Laboratory Network (MLN), managed by the Office of HIV/AIDS Network Coordination, is an international working group with mutual interests in malaria disease and diagnosis and in human immunodeficiency virus/acquired immunodeficiency syndrome clinical trials. The MLN considered and studied the wide array of available malaria diagnostic tests for their suitability for screening trial participants and/or obtaining study endpoints for malaria clinical trials, including studies of HIV/malaria co-infection and other malaria natural history studies. The MLN provides recommendations on microscopy, rapid diagnostic tests, serologic tests, and molecular assays to guide selection of the most appropriate test(s) for specific research objectives. In addition, this report provides recommendations regarding quality management to ensure reproducibility across sites in clinical trials. Performance evaluation, quality control, and external quality assessment are critical processes that must be implemented in all clinical trials using malaria tests.